ixekizumab vs secukinumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriatic Arthritis

Shared mechanism: IL-17 · full Psoriatic Arthritis pipeline

ixekizumab · Taltz

Marketed by Eli Lilly and partners

Approved in Psoriatic Arthritismonoclonal antibody
Reliable signal

NCT01695239 · Phase 3 · completed

This randomized, quadruple-blind, placebo- and active-comparator-controlled trial in 417 people with active psoriatic arthritis measured ACR20 response at week 24 as its primary endpoint. Both ixekizumab doses clearly outperformed placebo (57.9% and 62.1% vs 30.2%, p<0.001), and the active comparator adalimumab also beat placebo, confirming the trial could detect a true effect.

Next expected readout: February 2028 · NCT07443956 (registry estimate)

Reported efficacy

Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20) (Week 24): ACR20 response at week 24 (SPIRIT-P2): placebo 23/118 (20%) vs ixekizumab Q4W 65/122 (53%), effect size 33.8% (95% CI 22.4-45.2), p<0.0001; vs ixekizumab Q2W 59/123 (48%), effect size 28.5% (95% CI 17.1-39.8), p<0.0001 (met)

Result source: NCT02349295

secukinumab · Cosentyx

Marketed by Novartis

Approved in Psoriatic Arthritismonoclonal antibody
Reliable signal

NCT01392326 · Phase 3 · completed

In this large (n=606), randomized, quadruple-blind, placebo-controlled Phase 3 trial in active psoriatic arthritis, significantly more patients achieved an ACR20 response at week 24 on secukinumab 75 mg (50.5%) or 150 mg (50.0%) than on placebo (17.3%), a statistically significant difference for both doses (p<0.0001).

Next expected readout: October 2029 · NCT06751238 (registry estimate)

Reported efficacy

Proportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 28 (Baseline, Week 28): HAQ-DI response (>=0.35-point improvement) at Week 28: secukinumab 57.1% (32/56) vs ustekinumab 27.0% (17/63); OR 3.647 (95% CI 1.601-8.311), p=0.002. (met)

Result source: NCT04632927

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointixekizumabsecukinumab
ACR2053.3% vs 19.5%+33.8 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
7 other results
  • 48% vs 19.5% 80 mg Q2W · wk 24 · n 123 · Phase 3 · primary NCT02349295
  • 57.9% vs 30.2% Q4W · wk 24 · n 107 · Phase 3 · primary NCT01695239
  • 62.1% vs 30.2% Q2W · wk 24 · n 103 · Phase 3 · primary NCT01695239
  • 50% vs 22% 80 mg Q4W · wk 12 · n 122 · Phase 3 · secondary NCT02349295
  • 48% vs 22% 80 mg Q2W · wk 12 · n 123 · Phase 3 · secondary NCT02349295
  • 57% vs 31.1% Q4W · wk 12 · n 107 · Phase 3 · secondary NCT01695239
  • 60.2% vs 31.1% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01695239
51% vs 15.3%+35.7 vs placebo150 mg s.c. · wk 24 · n 100NCT01752634
17 other results
  • 42% vs 16.1% 150 mg · wk 24 · n 138 · Phase 3 · primary NCT01989468
  • 59.5% vs 27.4% 150 mg without load · wk 16 · n 222 · Phase 3 · primary NCT02404350
  • 55.5% vs 27.4% 150 mg with load · wk 16 · n 220 · Phase 3 · primary NCT02404350
  • 41.2% vs 18.4% 150 mg · wk 16 · n 114 · Phase 3 · primary NCT02294227
  • 39.8% vs 18.4% 150 mg · wk 16 · n 113 · Phase 3 · primary NCT02294227
  • 54% vs 15.3% 300 mg s.c. · wk 24 · n 100 · Phase 3 · primary NCT01752634
  • 48.2% vs 16.1% 300 mg · wk 24 · n 139 · Phase 3 · primary NCT01989468
  • 62.6% vs 27.4% 300 mg with load · wk 16 · n 222 · Phase 3 · primary NCT02404350
  • 29.3% vs 15.3% 75 mg s.c. · wk 24 · n 99 · Phase 3 · primary NCT01752634
  • 70% vs 28.6% 150 mg · wk 16 · n 20 · Phase 3 · primary NCT04711902
  • 67.4% vs 61.5% 300 mg s.c. · wk 52 · n 426 · Phase 3 · primary NCT02745080
  • 67.5% vs 31.3% 150 mg + 300 mg · wk 12 · n 83 · Phase 3 · secondary NCT02662985
  • 56.5% vs 18.5% 150 mg · wk 12 · n 157 · Phase 3 · secondary NCT02721966
  • 28.9% vs 19.3% 150 mg · wk 4 · n 114 · Phase 3 · secondary NCT02294227
  • 23% vs 19.3% 150 mg · wk 4 · n 113 · Phase 3 · secondary NCT02294227
  • 51.6% vs 18.5% 300 mg · wk 12 · n 164 · Phase 3 · secondary NCT02721966
  • 59.6% vs 29.0% 6 mg/kg - 3 mg/kg i.v. · wk 16 · n 191 · Phase 3 · secondary NCT04209205
ACR5035.2% vs 5.1%+30.1 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
4 other results
  • 33.3% vs 5.1% 80 mg Q2W · wk 24 · n 123 · Phase 3 · secondary NCT02349295
  • 40.2% vs 15.1% Q4W · wk 24 · n 107 · Phase 3 · secondary NCT01695239
  • 46.6% vs 15.1% Q2W · wk 24 · n 103 · Phase 3 · secondary NCT01695239
  • 50.5% vs 46.6% wk 24 · n 283 · Phase 4 · secondary NCT03151551
31.4% vs 6.3%+25 vs placebo6 mg/kg - 3 mg/kg i.v. · wk 16 · n 191NCT04209205
13 other results
  • 35% vs 7.1% 150 mg s.c. · wk 24 · n 100 · Phase 3 · secondary NCT01752634
  • 18.8% vs 8.8% 150 mg · wk 24 · n 138 · Phase 3 · secondary NCT01989468
  • 32% vs 8.1% 150 mg without load · wk 16 · n 222 · Phase 3 · secondary NCT02404350
  • 35.9% vs 8.1% 150 mg with load · wk 16 · n 220 · Phase 3 · secondary NCT02404350
  • 22.8% vs 6.1% 150 mg · wk 16 · n 114 · Phase 3 · secondary NCT02294227
  • 16.8% vs 6.1% 150 mg · wk 16 · n 113 · Phase 3 · secondary NCT02294227
  • 45.8% vs 8.4% 150 mg + 300 mg · wk 12 · n 83 · Phase 3 · secondary NCT02662985
  • 35% vs 7.1% 300 mg s.c. · wk 24 · n 100 · Phase 3 · secondary NCT01752634
  • 34.5% vs 8.8% 300 mg · wk 24 · n 139 · Phase 3 · secondary NCT01989468
  • 39.6% vs 8.1% 300 mg with load · wk 16 · n 222 · Phase 3 · secondary NCT02404350
  • 18.2% vs 7.1% 75 mg s.c. · wk 24 · n 99 · Phase 3 · secondary NCT01752634
  • 15% vs 4.8% 150 mg · wk 16 · n 20 · Phase 3 · secondary NCT04711902
  • 49% vs 44.8% 300 mg s.c. · wk 52 · n 426 · Phase 3 · secondary NCT02745080
PASI 7557.4% vs 10.4%+47 vs placebo80 mg Q4W · wk 12 · n 68NCT02349295
1 other result
  • 61.8% vs 10.4% 80 mg Q2W · wk 12 · n 68 · Phase 3 · secondary NCT02349295
48.3% vs 16.3%+32 vs placebo150 mg s.c. · wk 24 · n 58NCT01752634
10 other results
  • 50% vs 10.2% 150 mg · wk 24 · n 68 · Phase 3 · secondary NCT01989468
  • 58.1% vs 12.3% 150 mg without load · wk 16 · n 117 · Phase 3 · secondary NCT02404350
  • 60% vs 12.3% 150 mg with load · wk 16 · n 125 · Phase 3 · secondary NCT02404350
  • 52.7% vs 8.1% 150 mg · wk 16 · n 55 · Phase 3 · secondary NCT02294227
  • 50% vs 8.1% 150 mg · wk 16 · n 54 · Phase 3 · secondary NCT02294227
  • 63.4% vs 16.3% 300 mg s.c. · wk 24 · n 41 · Phase 3 · secondary NCT01752634
  • 46.8% vs 10.2% 300 mg · wk 24 · n 62 · Phase 3 · secondary NCT01989468
  • 70% vs 12.3% 300 mg with load · wk 16 · n 110 · Phase 3 · secondary NCT02404350
  • 28% vs 16.3% 75 mg s.c. · wk 24 · n 50 · Phase 3 · secondary NCT01752634
  • 60.7% vs 46% wk 28 · n 56 · Phase 3 · secondary NCT04632927
Minimal disease activity27.9% vs 3.4%+24.5 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
1 other result
  • 23.6% vs 3.4% 80 mg Q2W · wk 24 · n 123 · Phase 3 · secondary NCT02349295
22.4% vs 5.3%+17.2 vs placebo6 mg/kg - 3 mg/kg i.v. · wk 16 · n 191NCT04209205
1 other result
  • 35.7% vs 22.2% wk 28 · n 56 · Phase 3 · secondary NCT04632927
HAQ-DI, change-0.6 vs -0.2−0.4 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
5 other results
  • -0.4 vs -0.2 80 mg Q2W · wk 24 · n 123 · Phase 3 · secondary NCT02349295
  • -0.4 vs -0.2 Q4W · wk 24 · n 103 · Phase 3 · secondary NCT01695239
  • -0.5 vs -0.2 Q2W · wk 24 · n 98 · Phase 3 · secondary NCT01695239
  • -0.8 vs -0.7 n 51 · Phase 3 · secondary NCT02584855
  • -0.7 vs -0.6 wk 52 · n 242 · Phase 4 · secondary NCT03151551
-0.5 vs -0.3−0.2 vs placebo150 mg s.c. · wk 24 · n 95NCT01752634
12 other results
  • -0.3 vs -0.2 150 mg · wk 24 · n 138 · Phase 3 · secondary NCT01989468
  • -0.5 vs -0.2 150 mg without load · wk 16 · n 211 · Phase 3 · secondary NCT02404350
  • -0.4 vs -0.2 150 mg with load · wk 16 · n 210 · Phase 3 · secondary NCT02404350
  • -0.3 vs -0.2 150 mg · wk 12 · n 157 · Phase 3 · secondary NCT02721966
  • -0.6 vs -0.3 300 mg s.c. · wk 24 · n 95 · Phase 3 · secondary NCT01752634
  • -0.4 vs -0.2 300 mg · wk 24 · n 139 · Phase 3 · secondary NCT01989468
  • -0.6 vs -0.2 300 mg with load · wk 16 · n 211 · Phase 3 · secondary NCT02404350
  • -0.4 vs -0.2 300 mg · wk 12 · n 164 · Phase 3 · secondary NCT02721966
  • -0.3 vs -0.3 75 mg s.c. · wk 24 · n 89 · Phase 3 · secondary NCT01752634
  • -0.4 vs 0.1 6 mg/kg - 3 mg/kg i.v. · wk 16 · n 181 · Phase 3 · secondary NCT04209205
  • -0.3 vs 0.1 150 mg · wk 16 · n 19 · Phase 3 · secondary NCT04711902
  • -0.6 vs -0.6 300 mg s.c. · wk 52 · n 426 · Phase 3 · secondary NCT02745080

ACR20

ixekizumab
53.3% vs 19.5%+33.8 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
7 other results
  • 48% vs 19.5% 80 mg Q2W · wk 24 · n 123 · Phase 3 · primary NCT02349295
  • 57.9% vs 30.2% Q4W · wk 24 · n 107 · Phase 3 · primary NCT01695239
  • 62.1% vs 30.2% Q2W · wk 24 · n 103 · Phase 3 · primary NCT01695239
  • 50% vs 22% 80 mg Q4W · wk 12 · n 122 · Phase 3 · secondary NCT02349295
  • 48% vs 22% 80 mg Q2W · wk 12 · n 123 · Phase 3 · secondary NCT02349295
  • 57% vs 31.1% Q4W · wk 12 · n 107 · Phase 3 · secondary NCT01695239
  • 60.2% vs 31.1% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01695239
secukinumab
51% vs 15.3%+35.7 vs placebo150 mg s.c. · wk 24 · n 100NCT01752634
17 other results
  • 42% vs 16.1% 150 mg · wk 24 · n 138 · Phase 3 · primary NCT01989468
  • 59.5% vs 27.4% 150 mg without load · wk 16 · n 222 · Phase 3 · primary NCT02404350
  • 55.5% vs 27.4% 150 mg with load · wk 16 · n 220 · Phase 3 · primary NCT02404350
  • 41.2% vs 18.4% 150 mg · wk 16 · n 114 · Phase 3 · primary NCT02294227
  • 39.8% vs 18.4% 150 mg · wk 16 · n 113 · Phase 3 · primary NCT02294227
  • 54% vs 15.3% 300 mg s.c. · wk 24 · n 100 · Phase 3 · primary NCT01752634
  • 48.2% vs 16.1% 300 mg · wk 24 · n 139 · Phase 3 · primary NCT01989468
  • 62.6% vs 27.4% 300 mg with load · wk 16 · n 222 · Phase 3 · primary NCT02404350
  • 29.3% vs 15.3% 75 mg s.c. · wk 24 · n 99 · Phase 3 · primary NCT01752634
  • 70% vs 28.6% 150 mg · wk 16 · n 20 · Phase 3 · primary NCT04711902
  • 67.4% vs 61.5% 300 mg s.c. · wk 52 · n 426 · Phase 3 · primary NCT02745080
  • 67.5% vs 31.3% 150 mg + 300 mg · wk 12 · n 83 · Phase 3 · secondary NCT02662985
  • 56.5% vs 18.5% 150 mg · wk 12 · n 157 · Phase 3 · secondary NCT02721966
  • 28.9% vs 19.3% 150 mg · wk 4 · n 114 · Phase 3 · secondary NCT02294227
  • 23% vs 19.3% 150 mg · wk 4 · n 113 · Phase 3 · secondary NCT02294227
  • 51.6% vs 18.5% 300 mg · wk 12 · n 164 · Phase 3 · secondary NCT02721966
  • 59.6% vs 29.0% 6 mg/kg - 3 mg/kg i.v. · wk 16 · n 191 · Phase 3 · secondary NCT04209205

ACR50

ixekizumab
35.2% vs 5.1%+30.1 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
4 other results
  • 33.3% vs 5.1% 80 mg Q2W · wk 24 · n 123 · Phase 3 · secondary NCT02349295
  • 40.2% vs 15.1% Q4W · wk 24 · n 107 · Phase 3 · secondary NCT01695239
  • 46.6% vs 15.1% Q2W · wk 24 · n 103 · Phase 3 · secondary NCT01695239
  • 50.5% vs 46.6% wk 24 · n 283 · Phase 4 · secondary NCT03151551
secukinumab
31.4% vs 6.3%+25 vs placebo6 mg/kg - 3 mg/kg i.v. · wk 16 · n 191NCT04209205
13 other results
  • 35% vs 7.1% 150 mg s.c. · wk 24 · n 100 · Phase 3 · secondary NCT01752634
  • 18.8% vs 8.8% 150 mg · wk 24 · n 138 · Phase 3 · secondary NCT01989468
  • 32% vs 8.1% 150 mg without load · wk 16 · n 222 · Phase 3 · secondary NCT02404350
  • 35.9% vs 8.1% 150 mg with load · wk 16 · n 220 · Phase 3 · secondary NCT02404350
  • 22.8% vs 6.1% 150 mg · wk 16 · n 114 · Phase 3 · secondary NCT02294227
  • 16.8% vs 6.1% 150 mg · wk 16 · n 113 · Phase 3 · secondary NCT02294227
  • 45.8% vs 8.4% 150 mg + 300 mg · wk 12 · n 83 · Phase 3 · secondary NCT02662985
  • 35% vs 7.1% 300 mg s.c. · wk 24 · n 100 · Phase 3 · secondary NCT01752634
  • 34.5% vs 8.8% 300 mg · wk 24 · n 139 · Phase 3 · secondary NCT01989468
  • 39.6% vs 8.1% 300 mg with load · wk 16 · n 222 · Phase 3 · secondary NCT02404350
  • 18.2% vs 7.1% 75 mg s.c. · wk 24 · n 99 · Phase 3 · secondary NCT01752634
  • 15% vs 4.8% 150 mg · wk 16 · n 20 · Phase 3 · secondary NCT04711902
  • 49% vs 44.8% 300 mg s.c. · wk 52 · n 426 · Phase 3 · secondary NCT02745080

PASI 75

ixekizumab
57.4% vs 10.4%+47 vs placebo80 mg Q4W · wk 12 · n 68NCT02349295
1 other result
  • 61.8% vs 10.4% 80 mg Q2W · wk 12 · n 68 · Phase 3 · secondary NCT02349295
secukinumab
48.3% vs 16.3%+32 vs placebo150 mg s.c. · wk 24 · n 58NCT01752634
10 other results
  • 50% vs 10.2% 150 mg · wk 24 · n 68 · Phase 3 · secondary NCT01989468
  • 58.1% vs 12.3% 150 mg without load · wk 16 · n 117 · Phase 3 · secondary NCT02404350
  • 60% vs 12.3% 150 mg with load · wk 16 · n 125 · Phase 3 · secondary NCT02404350
  • 52.7% vs 8.1% 150 mg · wk 16 · n 55 · Phase 3 · secondary NCT02294227
  • 50% vs 8.1% 150 mg · wk 16 · n 54 · Phase 3 · secondary NCT02294227
  • 63.4% vs 16.3% 300 mg s.c. · wk 24 · n 41 · Phase 3 · secondary NCT01752634
  • 46.8% vs 10.2% 300 mg · wk 24 · n 62 · Phase 3 · secondary NCT01989468
  • 70% vs 12.3% 300 mg with load · wk 16 · n 110 · Phase 3 · secondary NCT02404350
  • 28% vs 16.3% 75 mg s.c. · wk 24 · n 50 · Phase 3 · secondary NCT01752634
  • 60.7% vs 46% wk 28 · n 56 · Phase 3 · secondary NCT04632927

Minimal disease activity

ixekizumab
27.9% vs 3.4%+24.5 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
1 other result
  • 23.6% vs 3.4% 80 mg Q2W · wk 24 · n 123 · Phase 3 · secondary NCT02349295
secukinumab
22.4% vs 5.3%+17.2 vs placebo6 mg/kg - 3 mg/kg i.v. · wk 16 · n 191NCT04209205
1 other result
  • 35.7% vs 22.2% wk 28 · n 56 · Phase 3 · secondary NCT04632927

HAQ-DI, change

ixekizumab
-0.6 vs -0.2−0.4 vs placebo80 mg Q4W · wk 24 · n 122NCT02349295
5 other results
  • -0.4 vs -0.2 80 mg Q2W · wk 24 · n 123 · Phase 3 · secondary NCT02349295
  • -0.4 vs -0.2 Q4W · wk 24 · n 103 · Phase 3 · secondary NCT01695239
  • -0.5 vs -0.2 Q2W · wk 24 · n 98 · Phase 3 · secondary NCT01695239
  • -0.8 vs -0.7 n 51 · Phase 3 · secondary NCT02584855
  • -0.7 vs -0.6 wk 52 · n 242 · Phase 4 · secondary NCT03151551
secukinumab
-0.5 vs -0.3−0.2 vs placebo150 mg s.c. · wk 24 · n 95NCT01752634
12 other results
  • -0.3 vs -0.2 150 mg · wk 24 · n 138 · Phase 3 · secondary NCT01989468
  • -0.5 vs -0.2 150 mg without load · wk 16 · n 211 · Phase 3 · secondary NCT02404350
  • -0.4 vs -0.2 150 mg with load · wk 16 · n 210 · Phase 3 · secondary NCT02404350
  • -0.3 vs -0.2 150 mg · wk 12 · n 157 · Phase 3 · secondary NCT02721966
  • -0.6 vs -0.3 300 mg s.c. · wk 24 · n 95 · Phase 3 · secondary NCT01752634
  • -0.4 vs -0.2 300 mg · wk 24 · n 139 · Phase 3 · secondary NCT01989468
  • -0.6 vs -0.2 300 mg with load · wk 16 · n 211 · Phase 3 · secondary NCT02404350
  • -0.4 vs -0.2 300 mg · wk 12 · n 164 · Phase 3 · secondary NCT02721966
  • -0.3 vs -0.3 75 mg s.c. · wk 24 · n 89 · Phase 3 · secondary NCT01752634
  • -0.4 vs 0.1 6 mg/kg - 3 mg/kg i.v. · wk 16 · n 181 · Phase 3 · secondary NCT04209205
  • -0.3 vs 0.1 150 mg · wk 16 · n 19 · Phase 3 · secondary NCT04711902
  • -0.6 vs -0.6 300 mg s.c. · wk 52 · n 426 · Phase 3 · secondary NCT02745080
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
12 other shared endpoints and safety

Coverage. ixekizumab: 16 of 16 rows · secukinumab: 16 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricixekizumab
Rows use multiple source trials
secukinumab
Rows use multiple source trials
Dactylitis
absolute change · score
-48.3 vs -25.4 placebo score @ 24wkQ2Wa,b,c,d
NCT01695239 · Phase 3
show 1 more dose
-57.1 vs -25.4 placebo score @ 24wkQ4W
NCT01695239 · Phase 3
3.08 vs 1.88 placebo score @ 24wk2x 10mg/kgb,c,d
NCT00809614 · Phase 2 · registry result, not featured evidence
DAS28-CRP
absolute change · score
-2.036 vs -0.835 placebo score @ 24wkQ2Wa,c,d
NCT01695239 · Phase 3
show 1 more dose
-1.955 vs -0.835 placebo score @ 24wkQ4W
NCT01695239 · Phase 3
-1.58 vs -0.96 placebo score @ 24wk150 mg s.c.a,c,d
NCT01752634 · Phase 3
show 2 more doses
-1.61 vs -0.96 placebo score @ 24wk300 mg s.c.
NCT01752634 · Phase 3
-1.12 vs -0.96 placebo score @ 24wk75 mg s.c.
NCT01752634 · Phase 3
Enthesitis Resolution
responder rate · % of participants
35.3% (n=68) vs 21.7% (n=69) placebo @ 24wk80 mg Q4Wa,e,d,f
NCT02349295 · Phase 3
show 1 more dose
31% (n=84) vs 21.7% (n=69) placebo @ 24wk80 mg Q2W
NCT02349295 · Phase 3
60.5% (n=234) vs 54.2% (n=264) Adalimumab @ 52wk300 mg s.c.e,d,f
NCT02745080 · Phase 3 · registry result, not featured evidence
Pain VAS
absolute change · score
-31.6 vs -14 placebo score @ 24wkQ2Wa,c,d,g
NCT01695239 · Phase 3
show 1 more dose
-29.6 vs -14 placebo score @ 24wkQ4W
NCT01695239 · Phase 3
-27.1 vs -16.4 Ustekinumab score @ 28wkc,d,g
NCT04632927 · Phase 3
PASI 100
responder rate · % of participants
60.1% (n=283) vs 46.6% (n=283) Adalimumab @ 24wkh,e,d,g
NCT03151551 · Phase 4 · registry result, not featured evidence
37.5% (n=56) vs 27% (n=63) Ustekinumab @ 28wk*h,e,d,g
NCT04632927 · Phase 3 · converted to % from 21 Participants as posted
Patient Global Assessment
absolute change · mm
-40.61 vs -37.82 Adalimumab mm @ 52wkh,e,d,i
NCT03151551 · Phase 4 · registry result, not featured evidence
-25.87 vs -16.61 placebo mm @ 24wkh,e,d,i
NCT02771210 · Phase 3 · registry result, not featured evidence
Physician Global Assessment
absolute change · mm
-48.15 vs -46.79 Adalimumab mm @ 52wkh,e,d,i
NCT03151551 · Phase 4 · registry result, not featured evidence
-34.88 vs -18.93 placebo mm @ 24wkh,e,d,i
NCT02771210 · Phase 3 · registry result, not featured evidence
PsARC
responder rate · % of participants
66% (n=103) vs 32.1% (n=106) placebo @ 24wkQ2Wa,b,c,d
NCT01695239 · Phase 3
show 1 more dose
57.9% (n=107) vs 32.1% (n=106) placebo @ 24wkQ4W
NCT01695239 · Phase 3
50% (n=24) vs 36% (n=13) placebo @ 24wk2x 10mg/kgb,c,d
NCT00809614 · Phase 2 · registry result, not featured evidence
SF-36 PCS
absolute change · score
10.07 vs 9.55 Adalimumab score @ 52wkh,e,d,j
NCT03151551 · Phase 4 · registry result, not featured evidence
4.28 vs 0.08 placebo score @ 16wk150 mgh,e,d,j
NCT04711902 · Phase 3 · registry result, not featured evidence
3 other source trials
6.47 vs 2.34 placebo score @ 16wk6 mg/kg - 3 mg/kg i.v.
NCT04209205 · Phase 3 · registry result, not featured evidence
3.42 vs 0.63 placebo score @ 16wk150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
3.44 vs 0.63 placebo score @ 16wk150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
SPARCC Enthesitis Index
absolute change · score
-3.93 vs -4.06 Adalimumab score @ 52wkh,e,d,k
NCT03151551 · Phase 4 · registry result, not featured evidence
-2.23 vs -1.57 placebo score @ 12wk150 mg + 300 mgh,e,d,k
NCT02662985 · Phase 3 · registry result, not featured evidence
2 other source trials
-2.2 vs -1.7 placebo score @ 12wk150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
-2.4 vs -1.7 placebo score @ 12wk300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
Swollen Joint Count
absolute change · score
-9.58 vs -9.53 Adalimumab score @ 52wkh,e,d,l
NCT03151551 · Phase 4 · registry result, not featured evidence
-6.8 vs -5.3 Ustekinumab score @ 28wkh,e,d,l
NCT04632927 · Phase 3
TJC
absolute change · score
-15.91 vs -14.88 Adalimumab score @ 52wkh,e,d,l
NCT03151551 · Phase 4 · registry result, not featured evidence
-9.6 vs -7.6 Ustekinumab score @ 28wkh,e,d,l
NCT04632927 · Phase 3
Dropout rate
—Q2Wm
NCT01695239 · Phase 3
show 22 more results
—Q4W
NCT01695239 · Phase 3
6.8%Q2W
NCT01695239 · Phase 3
9.3%Q4W
NCT01695239 · Phase 3
—Q2W
NCT01695239 · Phase 3
—Q4W
NCT01695239 · Phase 3
—80 mg Q4W
NCT02349295 · Phase 3
—80 mg Q4W
NCT02349295 · Phase 3
9%80 mg Q4W
NCT02349295 · Phase 3
—80 mg Q2W
NCT02349295 · Phase 3
—80 mg Q2W
NCT02349295 · Phase 3
11.4%80 mg Q2W
NCT02349295 · Phase 3
6%Ixekizumab - Active PsA
NCT05855967 · Phase 4 · registry result, not featured evidence
6%Ixekizumab - PsO With no Active Ps
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q2W/Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
6.4%Ixekizumab
NCT03151551 · Phase 4 · registry result, not featured evidence
—Ixekizumab Follow-up
NCT03151551 · Phase 4 · registry result, not featured evidence
—80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
—80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
—80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
—Ixekizumab
NCT02584855 · Phase 3 · registry result, not featured evidence
26.1%Ixekizumab Open Label
NCT02584855 · Phase 3 · registry result, not featured evidence
—150 mgm
NCT01392326 · Phase 3
show 46 more results
—75 mg
NCT01392326 · Phase 3
5%150 mg s.c.
NCT01752634 · Phase 3
3%300 mg s.c.
NCT01752634 · Phase 3
6.1%75 mg s.c.
NCT01752634 · Phase 3
0%Secukinumab
NCT04632927 · Phase 3
—Secukinumab - Entire Study
NCT04632927 · Phase 3
—Secukinumab- On-Treatment
NCT04632927 · Phase 3
—
NCT03031782 · Phase 3
2.7%150 mg with load
NCT02404350 · Phase 3
6.8%150 mg without load
NCT02404350 · Phase 3
2.7%300 mg with load
NCT02404350 · Phase 3
—150 mg
NCT02798211 · Phase 4 · registry result, not featured evidence
—300 mg
NCT02798211 · Phase 4 · registry result, not featured evidence
—150 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
66.7%150 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—300 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
47.4%75 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
—300 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
—6 mg/kg - 3 mg/kg i.v
NCT04209205 · Phase 3 · registry result, not featured evidence
9.4%6 mg/kg - 3 mg/kg i.v.
NCT04209205 · Phase 3 · registry result, not featured evidence
1.2%150 mg + 300 mg
NCT02662985 · Phase 3 · registry result, not featured evidence
—150+300 mg
NCT02662985 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02745080 · Phase 3 · registry result, not featured evidence
12.9%300 mg s.c.
NCT02745080 · Phase 3 · registry result, not featured evidence
10.8%
NCT02771210 · Phase 3 · registry result, not featured evidence
13.9%150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
17.4%300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
34.1%150 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
26.6%300 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
18.7%150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
18%150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
14.9%75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
15.6%75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
21.9%150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
22.1%150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
—3 mg/kg
NCT01169844 · Phase 2 · registry result, not featured evidence
10.7%2x 10mg/kg
NCT00809614 · Phase 2 · registry result, not featured evidence
—2x10mg/kg
NCT00809614 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—Q2Wm
NCT01695239 · Phase 3
show 22 more results
—Q4W
NCT01695239 · Phase 3
2.9%Q2W
NCT01695239 · Phase 3
1.9%Q4W
NCT01695239 · Phase 3
—Q2W
NCT01695239 · Phase 3
—Q4W
NCT01695239 · Phase 3
—80 mg Q4W
NCT02349295 · Phase 3
—80 mg Q4W
NCT02349295 · Phase 3
4.1%80 mg Q4W
NCT02349295 · Phase 3
—80 mg Q2W
NCT02349295 · Phase 3
—80 mg Q2W
NCT02349295 · Phase 3
5.7%80 mg Q2W
NCT02349295 · Phase 3
—Ixekizumab - Active PsA
NCT05855967 · Phase 4 · registry result, not featured evidence
—Ixekizumab - PsO With no Active Ps
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q2W/Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
0%Ixekizumab
NCT03151551 · Phase 4 · registry result, not featured evidence
—Ixekizumab Follow-up
NCT03151551 · Phase 4 · registry result, not featured evidence
—80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
—80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
—80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
—Ixekizumab
NCT02584855 · Phase 3 · registry result, not featured evidence
3.6%Ixekizumab Open Label
NCT02584855 · Phase 3 · registry result, not featured evidence
—150 mgm
NCT01392326 · Phase 3
show 46 more results
—75 mg
NCT01392326 · Phase 3
0%150 mg s.c.
NCT01752634 · Phase 3
2%300 mg s.c.
NCT01752634 · Phase 3
3%75 mg s.c.
NCT01752634 · Phase 3
0%Secukinumab
NCT04632927 · Phase 3
—Secukinumab - Entire Study
NCT04632927 · Phase 3
—Secukinumab- On-Treatment
NCT04632927 · Phase 3
—
NCT03031782 · Phase 3
0.9%150 mg with load
NCT02404350 · Phase 3
0.9%150 mg without load
NCT02404350 · Phase 3
1.4%300 mg with load
NCT02404350 · Phase 3
—150 mg
NCT02798211 · Phase 4 · registry result, not featured evidence
—300 mg
NCT02798211 · Phase 4 · registry result, not featured evidence
—150 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
2.8%150 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—300 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
0%75 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
—150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
—300 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
—6 mg/kg - 3 mg/kg i.v
NCT04209205 · Phase 3 · registry result, not featured evidence
1%6 mg/kg - 3 mg/kg i.v.
NCT04209205 · Phase 3 · registry result, not featured evidence
0%150 mg + 300 mg
NCT02662985 · Phase 3 · registry result, not featured evidence
—150+300 mg
NCT02662985 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02745080 · Phase 3 · registry result, not featured evidence
3.1%300 mg s.c.
NCT02745080 · Phase 3 · registry result, not featured evidence
4.9%
NCT02771210 · Phase 3 · registry result, not featured evidence
2.4%150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
2.4%300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
7.2%150 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
10.8%300 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
4%150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
3.7%150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
2.7%75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
4.8%75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
5.3%150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
7.1%150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
—3 mg/kg
NCT01169844 · Phase 2 · registry result, not featured evidence
—2x 10mg/kg
NCT00809614 · Phase 2 · registry result, not featured evidence
—2x10mg/kg
NCT00809614 · Phase 2 · registry result, not featured evidence
Serious AEs
0%Q2Wm
NCT01695239 · Phase 3
show 22 more results
0%Q4W
NCT01695239 · Phase 3
10.4%Q2W
NCT01695239 · Phase 3
15%Q4W
NCT01695239 · Phase 3
5.6%Q2W
NCT01695239 · Phase 3
2.9%Q4W
NCT01695239 · Phase 3
0%80 mg Q4W
NCT02349295 · Phase 3
11.7%80 mg Q4W
NCT02349295 · Phase 3
2.5%80 mg Q4W
NCT02349295 · Phase 3
0%80 mg Q2W
NCT02349295 · Phase 3
9.3%80 mg Q2W
NCT02349295 · Phase 3
6.5%80 mg Q2W
NCT02349295 · Phase 3
—Ixekizumab - Active PsA
NCT05855967 · Phase 4 · registry result, not featured evidence
—Ixekizumab - PsO With no Active Ps
NCT05855967 · Phase 4 · registry result, not featured evidence
0.5%Q2W/Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
0%Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
4.2%Ixekizumab
NCT03151551 · Phase 4 · registry result, not featured evidence
2.6%Ixekizumab Follow-up
NCT03151551 · Phase 4 · registry result, not featured evidence
4.5%80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
1.1%80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
1%80 mg every 2 weeks
NCT02584855 · Phase 3 · registry result, not featured evidence
1.3%Ixekizumab
NCT02584855 · Phase 3 · registry result, not featured evidence
5.1%Ixekizumab Open Label
NCT02584855 · Phase 3 · registry result, not featured evidence
17.3%150 mgm
NCT01392326 · Phase 3
show 46 more results
11%75 mg
NCT01392326 · Phase 3
—150 mg s.c.
NCT01752634 · Phase 3
—300 mg s.c.
NCT01752634 · Phase 3
—75 mg s.c.
NCT01752634 · Phase 3
—Secukinumab
NCT04632927 · Phase 3
7.1%Secukinumab - Entire Study
NCT04632927 · Phase 3
5.4%Secukinumab- On-Treatment
NCT04632927 · Phase 3
14.6%
NCT03031782 · Phase 3
4.1%150 mg with load
NCT02404350 · Phase 3
2.7%150 mg without load
NCT02404350 · Phase 3
3.2%300 mg with load
NCT02404350 · Phase 3
3.9%150 mg
NCT02798211 · Phase 4 · registry result, not featured evidence
7.9%300 mg
NCT02798211 · Phase 4 · registry result, not featured evidence
9.3%150 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
0%300 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
0%75 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
—150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
4.8%300 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
5.9%6 mg/kg - 3 mg/kg i.v
NCT04209205 · Phase 3 · registry result, not featured evidence
—6 mg/kg - 3 mg/kg i.v.
NCT04209205 · Phase 3 · registry result, not featured evidence
—150 mg + 300 mg
NCT02662985 · Phase 3 · registry result, not featured evidence
5.6%150+300 mg
NCT02662985 · Phase 3 · registry result, not featured evidence
8.7%300 mg
NCT02745080 · Phase 3 · registry result, not featured evidence
—300 mg s.c.
NCT02745080 · Phase 3 · registry result, not featured evidence
6.9%
NCT02771210 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
5.7%150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
5.6%300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
20.3%150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
6.1%300 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
16.4%75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
26.3%3 mg/kg
NCT01169844 · Phase 2 · registry result, not featured evidence
—2x 10mg/kg
NCT00809614 · Phase 2 · registry result, not featured evidence
14.3%2x10mg/kg
NCT00809614 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
Q2Wm
back pain 0% (placebo 0%)
bronchitis 0% (placebo 2.8%)
injection site erythema 0% (placebo 0%)
NCT01695239 · Phase 3
show 20 more results
Q4W
back pain 0% (placebo 0%)
bronchitis 0% (placebo 2.8%)
injection site erythema 0% (placebo 0%)
NCT01695239 · Phase 3
Q2W
viral upper respiratory tract infection 11.5% (placebo 4.7%)
upper respiratory tract infection 9.8% (placebo 6.6%)
injection site reaction 7.1% (placebo 0%)
NCT01695239 · Phase 3
Q4W
upper respiratory tract infection 11.2% (placebo 6.6%)
viral upper respiratory tract infection 11.2% (placebo 4.7%)
injection site reaction 6.4% (placebo 0%)
NCT01695239 · Phase 3
Q2W
injection site reaction 12.1% (placebo 0%)
injection site erythema 6.5% (placebo 0%)
viral upper respiratory tract infection 5.6% (placebo 4.7%)
NCT01695239 · Phase 3
Q4W
injection site reaction 15.7% (placebo 0%)
injection site erythema 12.7% (placebo 0%)
bronchitis 2.9% (placebo 2.8%)
NCT01695239 · Phase 3
80 mg Q4W
ear infection 6.7% (placebo 0.8%)
goitre 6.7% (placebo 0%)
hepatic steatosis 6.7% (placebo 0.8%)
NCT02349295 · Phase 3
80 mg Q4W
nasopharyngitis 18% (placebo 3.4%)
upper respiratory tract infection 13.5% (placebo 7.6%)
bronchitis 9.9% (placebo 3.4%)
NCT02349295 · Phase 3
80 mg Q4W
upper respiratory tract infection 9.8% (placebo 7.6%)
nasopharyngitis 7.4% (placebo 3.4%)
oropharyngeal pain 5.7% (placebo 0%)
NCT02349295 · Phase 3
80 mg Q2W
injection site pain 11.8% (placebo 1.7%)
injection site reaction 11.8% (placebo 0.8%)
vulvovaginal candidiasis 8.3% (placebo 0%)
NCT02349295 · Phase 3
80 mg Q2W
upper respiratory tract infection 18.7% (placebo 7.6%)
nasopharyngitis 14% (placebo 3.4%)
bronchitis 10.3% (placebo 3.4%)
NCT02349295 · Phase 3
80 mg Q2W
injection site reaction 12.2% (placebo 0.8%)
upper respiratory tract infection 9.8% (placebo 7.6%)
hypertension 4.9% (placebo 2.5%)
NCT02349295 · Phase 3
Q2W/Q4W
latent tuberculosis 8.6%
pyrexia 8.6%
injection site erythema 1.9%
NCT05855967 · Phase 4 · registry result, not featured evidence
Q4W
latent tuberculosis 9.8%
urinary tract infection 4.9%
c-reactive protein increased 2.4%
NCT05855967 · Phase 4 · registry result, not featured evidence
nasopharyngitis 13.4%
upper respiratory tract infection 6.4%
injection site reaction 5.7%
NCT03151551 · Phase 4 · registry result, not featured evidence
nasopharyngitis 1.9%
upper respiratory tract infection 1.1%
injection site reaction 0%
NCT03151551 · Phase 4 · registry result, not featured evidence
80 mg every 2 weeks
nasopharyngitis 14.3% (placebo 5.1%)
upper respiratory tract infection 9% (placebo 5.1%)
bronchitis 3.8% (placebo 1.3%)
NCT02584855 · Phase 3 · registry result, not featured evidence
80 mg every 2 weeks
upper respiratory tract infection 2.3% (placebo 5.1%)
psoriasis 1.1% (placebo 5.1%)
alanine aminotransferase increased 0.8% (placebo 1.3%)
NCT02584855 · Phase 3 · registry result, not featured evidence
80 mg every 2 weeks
nasopharyngitis 13.4% (placebo 5.1%)
upper respiratory tract infection 9.3% (placebo 5.1%)
injection site reaction 7.2% (placebo 0%)
NCT02584855 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.9% (placebo 5.1%)
upper respiratory tract infection 11.4% (placebo 5.1%)
uterine leiomyoma 6.3% (placebo 0%)
NCT02584855 · Phase 3 · registry result, not featured evidence
injection site reaction 15% (placebo 0%)
upper respiratory tract infection 12.4% (placebo 5.1%)
nasopharyngitis 8.6% (placebo 5.1%)
NCT02584855 · Phase 3 · registry result, not featured evidence
150 mgm
upper respiratory tract infection 20.3% (placebo 5.9%)
nasopharyngitis 18.3% (placebo 5.4%)
headache 8.5% (placebo 3.5%)
NCT01392326 · Phase 3
show 25 more results
75 mg
nasopharyngitis 20.9% (placebo 5.4%)
upper respiratory tract infection 17.8% (placebo 5.9%)
back pain 9.9% (placebo 1%)
NCT01392326 · Phase 3
nasopharyngitis 12.5%
covid-19 10.7%
arthralgia 8.9%
NCT04632927 · Phase 3
covid-19 10.7%
arthralgia 8.9%
diarrhoea 8.9%
NCT04632927 · Phase 3
nasopharyngitis 33.3% (placebo 28.9%)
diarrhoea 22.9% (placebo 15.8%)
nausea 22.9% (placebo 21.1%)
NCT03031782 · Phase 3
150 mg with load
upper respiratory tract infection 7.7% (placebo 3.3%)
viral upper respiratory tract infection 6.8% (placebo 8.7%)
pruritus 5% (placebo 1.2%)
NCT02404350 · Phase 3
150 mg without load
upper respiratory tract infection 6.3% (placebo 3.3%)
viral upper respiratory tract infection 5.9% (placebo 8.7%)
hypertension 4.1% (placebo 3%)
NCT02404350 · Phase 3
300 mg with load
viral upper respiratory tract infection 6.3% (placebo 8.7%)
diarrhoea 4.1% (placebo 6.6%)
bronchitis 3.6% (placebo 0.6%)
NCT02404350 · Phase 3
150 mg
back pain 7.8% (placebo 15.4%)
diarrhoea 6.8% (placebo 3.8%)
hypertension 5.8% (placebo 0%)
NCT02798211 · Phase 4 · registry result, not featured evidence
300 mg
upper respiratory tract infection 13.6% (placebo 1.9%)
diarrhoea 5.8% (placebo 3.8%)
back pain 5.2% (placebo 15.4%)
NCT02798211 · Phase 4 · registry result, not featured evidence
150 mg
covid-19 20.9%
nasopharyngitis 18.6%
pain in extremity 18.6%
NCT03769168 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 25%
arthralgia 18.8%
covid-19 18.8%
NCT03769168 · Phase 3 · registry result, not featured evidence
75 mg
arthralgia 21.1%
abdominal pain upper 15.8%
back pain 10.5%
NCT03769168 · Phase 3 · registry result, not featured evidence
150 mg
hyperlipidaemia 20% (placebo 38.1%)
hypercholesterolaemia 16.7% (placebo 0%)
hyperuricaemia 16.7% (placebo 9.5%)
NCT04711902 · Phase 3 · registry result, not featured evidence
300 mg
covid-19 23.8% (placebo 0%)
hyperuricaemia 19% (placebo 9.5%)
hyperlipidaemia 14.3% (placebo 38.1%)
NCT04711902 · Phase 3 · registry result, not featured evidence
6 mg/kg - 3 mg/kg i.v
covid-19 9.9% (placebo 3.7%)
urinary tract infection 4.5% (placebo 0.5%)
arthralgia 3.7% (placebo 1.6%)
NCT04209205 · Phase 3 · registry result, not featured evidence
150+300 mg
nasopharyngitis 11.8% (placebo 4.8%)
headache 8.1% (placebo 3.6%)
urinary tract infection 6.2% (placebo 3.6%)
NCT02662985 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 20.7%
upper respiratory tract infection 9.9%
headache 8.5%
NCT02745080 · Phase 3 · registry result, not featured evidence
nasopharyngitis 12.7%
diarrhoea 7.8%
arthralgia 6.9%
NCT02771210 · Phase 3 · registry result, not featured evidence
150 mg
nasopharyngitis 9% (placebo 6.6%)
upper respiratory tract infection 5.7% (placebo 3%)
pharyngitis 5.3% (placebo 3%)
NCT02721966 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 13.7% (placebo 6.6%)
diarrhoea 6.5% (placebo 2.4%)
upper respiratory tract infection 4.8% (placebo 3%)
NCT02721966 · Phase 3 · registry result, not featured evidence
150 mg
nasopharyngitis 21.4% (placebo 5.4%)
upper respiratory tract infection 19.2% (placebo 5.9%)
headache 8.9% (placebo 3.5%)
NCT01892436 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 8.5% (placebo 5.4%)
upper respiratory tract infection 6.1% (placebo 5.9%)
bronchitis 5.5% (placebo 3%)
NCT01892436 · Phase 3 · registry result, not featured evidence
75 mg
nasopharyngitis 24% (placebo 5.4%)
upper respiratory tract infection 21.2% (placebo 5.9%)
headache 10.6% (placebo 3.5%)
NCT01892436 · Phase 3 · registry result, not featured evidence
3 mg/kg
nasopharyngitis 36.8% (placebo 44.4%)
arthralgia 26.3% (placebo 22.2%)
oropharyngeal pain 26.3% (placebo 33.3%)
NCT01169844 · Phase 2 · registry result, not featured evidence
2x10mg/kg
nasopharyngitis 25% (placebo 35.7%)
headache 21.4% (placebo 7.1%)
dizziness 14.3% (placebo 0%)
NCT00809614 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 3.
  3. cPopulation context differs: registered conditions differ.
  4. dTreatment context has not been resolved for both arms.
  5. ePopulation comparability has not been reviewed for both studies.
  6. fAssessment timepoints differ: 52 weeks versus 24 weeks.
  7. gAssessment timepoints differ: 28 weeks versus 24 weeks.
  8. hTrial phases differ: Phase 3 versus Phase 4.
  9. iAssessment timepoints differ: 24 weeks versus 52 weeks.
  10. jAssessment timepoints differ: 16 weeks versus 52 weeks.
  11. kAssessment timepoints differ: 12 weeks versus 52 weeks.
  12. lAssessment timepoints differ: 28 weeks versus 52 weeks.
  13. mPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ixekizumab

ACR70 22.1% (n=122) vs 0% (n=118) placebo @ 24wk80 mg Q4W
responder rate · % of participants
NCT02349295 · Phase 3
show 3 more results
12.2% (n=123) vs 0% (n=118) placebo @ 24wk80 mg Q2W
NCT02349295 · Phase 3
23.4% (n=107) vs 5.7% (n=106) placebo @ 24wkQ4W
NCT01695239 · Phase 3
34% (n=103) vs 5.7% (n=106) placebo @ 24wkQ2W
NCT01695239 · Phase 3
Modified Sharp 0.17 vs 0.49 placebo score @ 24wkQ4W
absolute change · score
NCT01695239 · Phase 3
show 1 more result
0.08 vs 0.49 placebo score @ 24wkQ2W
NCT01695239 · Phase 3
PASI 75 75.3% (n=73) vs 7.5% (n=67) placebo @ 12wkQ4W
responder rate · % of participants
PASI 75
NCT01695239 · Phase 3
show 3 more results
69.5% (n=59) vs 7.5% (n=67) placebo @ 12wkQ2W
PASI 75
NCT01695239 · Phase 3
71.2% (n=60) vs 10.9% (n=38) placebo @ 24wkQ4W
PASI 75
NCT01695239 · Phase 3
80.4% (n=49) vs 10.9% (n=38) placebo @ 24wkQ2W
PASI 75
NCT01695239 · Phase 3
PASI 90 52.1% (n=73) vs 1.5% (n=67) placebo @ 12wkQ4W
responder rate · % of participants
PASI 90
NCT01695239 · Phase 3
show 3 more results
57.6% (n=59) vs 1.5% (n=67) placebo @ 12wkQ2W
PASI 90
NCT01695239 · Phase 3
56.2% (n=60) vs 6.3% (n=38) placebo @ 24wkQ4W
PASI 90
NCT01695239 · Phase 3
67.9% (n=49) vs 6.3% (n=38) placebo @ 24wkQ2W
PASI 90
NCT01695239 · Phase 3
PASI 100 31.5% (n=73) vs 1.5% (n=67) placebo @ 12wkQ4W
responder rate · % of participants
PASI 100
NCT01695239 · Phase 3
show 3 more results
40.7% (n=59) vs 1.5% (n=67) placebo @ 12wkQ2W
PASI 100
NCT01695239 · Phase 3
42.5% (n=60) vs 3.1% (n=38) placebo @ 24wkQ4W
PASI 100
NCT01695239 · Phase 3
53.6% (n=49) vs 3.1% (n=38) placebo @ 24wkQ2W
PASI 100
NCT01695239 · Phase 3
Enthesitis -0.9 vs -0.8 placebo score @ 12wkQ4W
absolute change · score
NCT01695239 · Phase 3
show 3 more results
-1.5 vs -0.8 placebo score @ 12wkQ2W
NCT01695239 · Phase 3
-1.3 vs -0.8 placebo score @ 24wkQ4W
NCT01695239 · Phase 3
-1.4 vs -0.8 placebo score @ 24wkQ2W
NCT01695239 · Phase 3
Itch NRS -3.4 vs -0.7 placebo score @ 12wk80 mg Q4W
absolute change · score
NCT02349295 · Phase 3
show 6 more results
-3.3 vs -0.7 placebo score @ 12wk80 mg Q2W
NCT02349295 · Phase 3
-2.6 vs 0.2 placebo score @ 12wkQ4W
NCT01695239 · Phase 3
-2.8 vs 0.2 placebo score @ 12wkQ2W
NCT01695239 · Phase 3
-2.9 vs -0.3 placebo score @ 24wkQ4W
NCT01695239 · Phase 3
-2.8 vs -0.3 placebo score @ 24wkQ2W
NCT01695239 · Phase 3
-3.83 vs -3.54 Adalimumab score @ 52wk
NCT03151551 · Phase 4 · registry result, not featured evidence
Fatigue NRS -2 vs -0.7 placebo score @ 24wk80 mg Q4W
absolute change · score
NCT02349295 · Phase 3
show 4 more results
-2.1 vs -0.7 placebo score @ 24wk80 mg Q2W
NCT02349295 · Phase 3
-1.6 vs -1.3 placebo score @ 24wkQ4W
NCT01695239 · Phase 3
-1.9 vs -1.3 placebo score @ 24wkQ2W
NCT01695239 · Phase 3
-3.03 vs -2.95 Adalimumab score @ 52wk
NCT03151551 · Phase 4 · registry result, not featured evidence
SF-36 PCS 7.45 vs 2.94 placebo score @ 24wkQ4W
absolute change · score
PCS Score
NCT01695239 · Phase 3
show 1 more result
8.24 vs 2.94 placebo score @ 24wkQ2W
PCS Score
NCT01695239 · Phase 3
SF-36 Mental Component Summary 4.86 vs 2.67 placebo score @ 24wkQ4W
absolute change · score
MCS Score
NCT01695239 · Phase 3
show 1 more result
3.39 vs 2.67 placebo score @ 24wkQ2W
MCS Score
NCT01695239 · Phase 3
QIDS-SR16 -0.8 vs -0.9 placebo score @ 24wkQ4W
absolute change · score
NCT01695239 · Phase 3
show 1 more result
-0.7 vs -0.9 placebo score @ 24wkQ2W
NCT01695239 · Phase 3
sPGA 0/1 65.4% (n=52) vs 17.1% (n=41) placebo @ 24wkQ4W
responder rate · % of participants
NCT01695239 · Phase 3
show 1 more result
73.2% (n=41) vs 17.1% (n=41) placebo @ 24wkQ2W
NCT01695239 · Phase 3

+ 28 further endpoints in the CSV export.

secukinumab

PASI 90 32.8% (n=58) vs 9.3% (n=43) placebo @ 24wk150 mg s.c.
responder rate · % of participants
NCT01752634 · Phase 3 · converted to % from 19 Participants as posted
show 10 more results
31.6% (n=117) vs 9.3% (n=162) placebo @ 16wk*150 mg without load
NCT02404350 · Phase 3 · converted to % from 37 Participants as posted
36.8% (n=125) vs 9.3% (n=162) placebo @ 16wk*150 mg with load
NCT02404350 · Phase 3 · converted to % from 46 Participants as posted
36.8% (n=68) vs 6.8% (n=59) placebo @ 24wk*150 mg
NCT01989468 · Phase 3 · registry result, not featured evidence · converted to % from 25 Participants as posted
48.8% (n=41) vs 9.3% (n=43) placebo @ 24wk*300 mg s.c.
NCT01752634 · Phase 3 · converted to % from 20 Participants as posted
53.6% (n=110) vs 9.3% (n=162) placebo @ 16wk*300 mg with load
NCT02404350 · Phase 3 · converted to % from 59 Participants as posted
65.4% (n=215) vs 43.2% (n=202) Adalimumab @ 52wk300 mg s.c.
NCT02745080 · Phase 3 · registry result, not featured evidence
33.9% (n=62) vs 6.8% (n=59) placebo @ 24wk*300 mg
NCT01989468 · Phase 3 · registry result, not featured evidence · converted to % from 21 Participants as posted
12% (n=50) vs 9.3% (n=43) placebo @ 24wk*75 mg s.c.
NCT01752634 · Phase 3 · converted to % from 6 Participants as posted
47.85% (n=49) vs 6.46% (n=7) placebo @ 16wk6 mg/kg - 3 mg/kg i.v.
NCT04209205 · Phase 3 · registry result, not featured evidence
48.2% (n=56) vs 39.7% (n=63) Ustekinumab @ 28wk*
NCT04632927 · Phase 3 · converted to % from 27 Participants as posted
SF-36 Physical Component 6.39 vs 1.95 placebo score @ 24wk150 mg s.c.
absolute change · score
NCT01752634 · Phase 3
show 2 more results
7.25 vs 1.95 placebo score @ 24wk300 mg s.c.
NCT01752634 · Phase 3
4.38 vs 1.95 placebo score @ 24wk75 mg s.c.
NCT01752634 · Phase 3
HAQ-DI 57.1% (n=56) vs 27% (n=63) Ustekinumab @ 28wk
responder rate · % of participants
NCT04632927 · Phase 3 · converted to % from 32 Participants as posted
PtGA -26 vs -15.5 Ustekinumab score @ 28wk
absolute change · score
NCT04632927 · Phase 3
show 1 more result
-28.1 vs -16.2 Ustekinumab score @ 28wk
NCT04632927 · Phase 3
LEI -0.9 vs -0.5 Ustekinumab score @ 28wk
absolute change · score
NCT04632927 · Phase 3
PsAQoL -2.5 vs -2 Ustekinumab score @ 28wk
absolute change · score
NCT04632927 · Phase 3
FACIT-Fatigue 71.4% (n=56) vs 50.8% (n=63) Ustekinumab @ 28wk
responder rate · % of participants
NCT04632927 · Phase 3 · converted to % from 40 Participants as posted
DLQI ≥4 53.6% (n=56) vs 50.8% (n=63) Ustekinumab @ 28wk
responder rate · % of participants
NCT04632927 · Phase 3 · converted to % from 30 Participants as posted
Flare 27% (n=37) vs 55.3% (n=38) placebo @ 104wk
event count · % of participants
NCT03031782 · Phase 3 · converted to % from 10 Participants as posted
ACR30 90.4% (n=86) @ 12wk
responder rate · % of participants
No placebo or comparator arm
ACR 30
NCT03031782 · Phase 3
ACR50 86.7% (n=86) @ 12wk
responder rate · % of participants
No placebo or comparator arm
ACR 50
NCT03031782 · Phase 3
ACR70 69.9% (n=86) @ 12wk
responder rate · % of participants
No placebo or comparator arm
ACR 70
NCT03031782 · Phase 3

+ 81 further endpoints in the CSV export.

Psoriasis

Shared mechanism: IL-17 · full Psoriasis pipeline

ixekizumab · Taltz

Marketed by Eli Lilly and partners

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT01474512 · Phase 3 · completed

The study was randomized, quadruple-blind, placebo-controlled, and included 1,296 participants. Its clinical primary endpoints, sPGA 0/1 and PASI75 at Week 12, were met for both ixekizumab regimens versus placebo, with p<0.001 for each comparison.

Next expected readout: December 2027 · NCT04537689 (registry estimate)

Reported efficacy

Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 (Efficacy of Ixekizumab in Participants With Active Psoriatic Arthritis. Measure: American College of Rheumatology 20 Index [ACR20]): ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo. (met)

Result source: NCT01695239

secukinumab · Cosentyx

Marketed by Novartis

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT01358578 · Phase 3 · completed

This was a large, randomized, quadruple-blind trial with both placebo and active etanercept comparator groups, enrolling 1,306 participants. The clinical primary endpoints at week 12 were met in the favorable direction based on the reported counts: PASI 75 and IGA 0/1 responses were achieved by large majorities of secukinumab-treated participants compared with very few placebo-treated participants, although formal statistical analyses are not posted in the registry.

Next expected readout: December 2027 · NCT04239859 (registry estimate)

Reported efficacy

Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks); Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure:IGA (Investigator's Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12 (12 wks): Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks): AIN457 150mg 219/327 (67.0%) | AIN457 300mg 249/323 (77.1%) vs Placebo 16/324 (4.9%) (met)

Result source: NCT01358578

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointixekizumabsecukinumab
PASI 7584.2% vs 7.3%+76.9 vs placebo80 mg every 4 weeks · wk 12 · n 386NCT01646177
16 other results
  • 87.3% vs 7.3% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · primary NCT01646177
  • 87.4% vs 8% 80 mg Q4W · wk 12 · n 174 · Phase 3 · primary NCT03364309
  • 93.8% vs 8% 80 mg Q2W · wk 12 · n 176 · Phase 3 · primary NCT03364309
  • 82.6% vs 3.9% Q4W · wk 12 · n 432 · Phase 3 · primary NCT01474512
  • 89.1% vs 3.9% Q2W · wk 12 · n 433 · Phase 3 · primary NCT01474512
  • 77.5% vs 2.4% Q4W · wk 12 · n 347 · Phase 3 · primary NCT01597245
  • 89.7% vs 2.4% Q2W · wk 12 · n 351 · Phase 3 · primary NCT01597245
  • 88.7% vs 25% wk 12 · n 115 · Phase 3 · primary NCT03073200
  • 53.9% vs 8.9% wk 4 · n 115 · Phase 3 · secondary NCT03073200
  • 84.2% vs 26.3% wk 12 · n 38 · Phase 3 · secondary NCT03073200
  • 88.2% vs 68.7% wk 12 · n 136 · Phase 3 · secondary NCT02561806
  • 82.1% vs 7.7% 150 mg · wk 12 · n 28 · Phase 2 · primary NCT01107457
  • 82.8% vs 7.7% 75 mg · wk 12 · n 29 · Phase 2 · primary NCT01107457
  • 76.7% vs 7.7% 25 mg · wk 12 · n 30 · Phase 2 · primary NCT01107457
  • 28.6% vs 7.7% 10 mg · wk 12 · n 28 · Phase 2 · primary NCT01107457
  • 22.9% vs 5.1% wk 2 · n 520 · Phase 4 · secondary NCT03573323
77.1% vs 4.9%+72.2 vs placebo300mg · wk 12 · n 323NCT01358578
27 other results
  • 81.6% vs 4.5% 300 mg · wk 12 · n 245 · Phase 3 · primary NCT01365455
  • 93.4% vs 4.4% 300 mg · wk 12 · n 272 · Phase 3 · primary NCT03066609
  • 67% vs 4.9% 150mg · wk 12 · n 327 · Phase 3 · primary NCT01358578
  • 71.6% vs 4.5% 150 mg · wk 12 · n 243 · Phase 3 · primary NCT01365455
  • 75.9% vs 0% 300 mg · wk 12 · n 58 · Phase 3 · primary NCT01555125
  • 82.4% vs 4.4% 150 mg · wk 12 · n 136 · Phase 3 · primary NCT03066609
  • 95.1% vs 10% 300 mg · wk 12 · n 41 · Phase 3 · primary NCT03589885
  • 69.5% vs 0% 150 mg · wk 12 · n 59 · Phase 3 · primary NCT01555125
  • 88.9% vs 1.4% 2 mL PFS · wk 12 · n 72 · Phase 3 · primary NCT02748863
  • 80% vs 14.6% low dose · wk 12 · n 40 · Phase 3 · primary NCT02471144
  • 77.5% vs 14.6% high dose · wk 12 · n 40 · Phase 3 · primary NCT02471144
  • 64.7% vs 2% wk 12 · n 51 · Phase 3 · secondary NCT02267135
  • 77.1% vs 44% 300mg · wk 12 · n 323 · Phase 3 · secondary NCT01358578
  • 88% vs 74.1% 300 mg · wk 12 · n 550 · Phase 3 · secondary NCT02826603
  • 92% vs 79.9% 300 mg · wk 16 · n 550 · Phase 3 · secondary NCT02826603
  • 40.2% vs 16.3% 300 mg · wk 4 · n 550 · Phase 3 · secondary NCT02826603
  • 49.7% vs 20.6% 300 mg · wk 4 · n 334 · Phase 3 · secondary NCT02074982
  • 67% vs 44% 150mg · wk 12 · n 327 · Phase 3 · secondary NCT01358578
  • 87.6% vs 21.1% wk 12 · n 105 · Phase 3 · secondary NCT02474082
  • 80% vs 8.4% wk 8 · n 105 · Phase 3 · secondary NCT02474082
  • 88.6% vs 27.4% wk 16 · n 105 · Phase 3 · secondary NCT02474082
  • 69.5% vs 2.1% wk 6 · n 105 · Phase 3 · secondary NCT02474082
  • 47.6% vs 1.1% wk 4 · n 105 · Phase 3 · secondary NCT02474082
  • 24.8% vs 0% wk 3 · n 105 · Phase 3 · secondary NCT02474082
  • 5.7% vs 0% wk 2 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 1 · n 105 · Phase 3 · secondary NCT02474082
  • 84.8% vs 0% wk 12 · n 46 · Phase 4 · secondary NCT02690701
PASI 9072.8% vs 42.2%vs Ustekinumabwk 12 · n 136NCT02561806
9 other results
  • 65.3% vs 3.1% 80 mg every 4 weeks · wk 12 · n 386 · Phase 3 · secondary NCT01646177
  • 68.1% vs 3.1% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · secondary NCT01646177
  • 75.9% vs 2.3% 80 mg Q4W · wk 12 · n 174 · Phase 3 · secondary NCT03364309
  • 82.4% vs 2.3% 80 mg Q2W · wk 12 · n 176 · Phase 3 · secondary NCT03364309
  • 59.7% vs 0.6% Q4W · wk 12 · n 347 · Phase 3 · secondary NCT01597245
  • 70.7% vs 0.6% Q2W · wk 12 · n 351 · Phase 3 · secondary NCT01597245
  • 78.3% vs 5.4% wk 12 · n 115 · Phase 3 · secondary NCT03073200
  • 58.5% vs 35.9% wk 8 · n 520 · Phase 4 · secondary NCT03573323
  • 21% vs 7.9% wk 4 · n 520 · Phase 4 · secondary NCT03573323
66.5% vs 48%vs Ustekinumab300 mg · wk 12 · n 550NCT02826603
23 other results
  • 79% vs 57.3% 300 mg · wk 16 · n 334 · Phase 3 · primary NCT02074982
  • 54.2% vs 1.5% 300mg · wk 12 · n 323 · Phase 3 · secondary NCT01358578
  • 59.2% vs 1.2% 300 mg · wk 12 · n 245 · Phase 3 · secondary NCT01365455
  • 77.2% vs 1.5% 300 mg · wk 12 · n 272 · Phase 3 · secondary NCT03066609
  • 41.9% vs 1.5% 150mg · wk 12 · n 327 · Phase 3 · secondary NCT01358578
  • 39.1% vs 1.2% 150 mg · wk 12 · n 243 · Phase 3 · secondary NCT01365455
  • 62.5% vs 1.5% 150 mg · wk 12 · n 136 · Phase 3 · secondary NCT03066609
  • 75.6% vs 5% 300 mg · wk 12 · n 41 · Phase 3 · secondary NCT03589885
  • 47.1% vs 0% wk 12 · n 51 · Phase 3 · secondary NCT02267135
  • 66.7% vs 1.4% 2 mL PFS · wk 12 · n 72 · Phase 3 · secondary NCT02748863
  • 72.5% vs 2.4% low dose · wk 12 · n 40 · Phase 3 · secondary NCT02471144
  • 67.5% vs 2.4% high dose · wk 12 · n 40 · Phase 3 · secondary NCT02471144
  • 76.9% vs 54.2% 300 mg · wk 16 · n 550 · Phase 3 · secondary NCT02826603
  • 63.8% vs 2.1% wk 12 · n 105 · Phase 3 · secondary NCT02474082
  • 46.7% vs 1.1% wk 8 · n 105 · Phase 3 · secondary NCT02474082
  • 68.6% vs 8.4% wk 16 · n 105 · Phase 3 · secondary NCT02474082
  • 32.4% vs 0% wk 6 · n 105 · Phase 3 · secondary NCT02474082
  • 17.1% vs 0% wk 4 · n 105 · Phase 3 · secondary NCT02474082
  • 2.9% vs 0% wk 3 · n 105 · Phase 3 · secondary NCT02474082
  • 1.9% vs 0% wk 2 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 1 · n 105 · Phase 3 · secondary NCT02474082
  • 53.7% vs 0% 300 mg · wk 12 · n 54 · Phase 4 · primary NCT03055494
  • 73.9% vs 0% wk 12 · n 46 · Phase 4 · secondary NCT02690701
PASI 10035% vs 0%+35 vs placebo80 mg every 4 weeks · wk 12 · n 386NCT01646177
10 other results
  • 37.7% vs 0% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · secondary NCT01646177
  • 29.3% vs 0% 80 mg Q4W · wk 12 · n 174 · Phase 3 · secondary NCT03364309
  • 33% vs 0% 80 mg Q2W · wk 12 · n 176 · Phase 3 · secondary NCT03364309
  • 30.8% vs 0.6% Q4W · wk 12 · n 347 · Phase 3 · secondary NCT01597245
  • 40.5% vs 0.6% Q2W · wk 12 · n 351 · Phase 3 · secondary NCT01597245
  • 49.6% vs 1.8% wk 12 · n 115 · Phase 3 · secondary NCT03073200
  • 36% vs 14.5% wk 12 · n 136 · Phase 3 · secondary NCT02561806
  • 41.3% vs 24.9% wk 12 · n 520 · Phase 4 · primary NCT03573323
  • 29.6% vs 13.6% wk 8 · n 520 · Phase 4 · secondary NCT03573323
  • 6.7% vs 1.4% wk 4 · n 520 · Phase 4 · secondary NCT03573323
23.5% vs 0%+23.5 vs placebowk 12 · n 51NCT02267135
13 other results
  • 38.9% vs 0% 2 mL PFS · wk 12 · n 72 · Phase 3 · secondary NCT02748863
  • 36.6% vs 0% 2 x 1 mL PFS · wk 12 · n 71 · Phase 3 · secondary NCT02748863
  • 38.2% vs 20.1% 300 mg · wk 12 · n 550 · Phase 3 · secondary NCT02826603
  • 45.5% vs 26.6% 300 mg · wk 16 · n 550 · Phase 3 · secondary NCT02826603
  • 28.6% vs 0% wk 12 · n 105 · Phase 3 · secondary NCT02474082
  • 15.2% vs 0% wk 8 · n 105 · Phase 3 · secondary NCT02474082
  • 37.1% vs 0% wk 16 · n 105 · Phase 3 · secondary NCT02474082
  • 7.6% vs 0% wk 6 · n 105 · Phase 3 · secondary NCT02474082
  • 3.8% vs 0% wk 4 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 3 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 2 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 1 · n 105 · Phase 3 · secondary NCT02474082
  • 37% vs 0% wk 12 · n 46 · Phase 4 · secondary NCT02690701
sPGA 0/175.4% vs 6.7%+68.7 vs placebo80 mg every 4 weeks · wk 12 · n 386NCT01646177
16 other results
  • 80.5% vs 6.7% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · primary NCT01646177
  • 79.9% vs 3.4% 80 mg Q4W · wk 12 · n 174 · Phase 3 · primary NCT03364309
  • 86.4% vs 3.4% 80 mg Q2W · wk 12 · n 176 · Phase 3 · primary NCT03364309
  • 76.4% vs 3.2% Q4W · wk 12 · n 432 · Phase 3 · primary NCT01474512
  • 81.8% vs 3.2% Q2W · wk 12 · n 433 · Phase 3 · primary NCT01474512
  • 72.9% vs 2.4% Q4W · wk 12 · n 347 · Phase 3 · primary NCT01597245
  • 83.2% vs 2.4% Q2W · wk 12 · n 351 · Phase 3 · primary NCT01597245
  • 80.9% vs 10.7% wk 12 · n 115 · Phase 3 · primary NCT03073200
  • 73.3% vs 2.7% 80mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT02718898
  • 47.8% vs 7.1% wk 4 · n 115 · Phase 3 · secondary NCT03073200
  • 76.3% vs 5.3% wk 12 · n 38 · Phase 3 · secondary NCT03073200
  • 83.6% vs 57.2% wk 12 · n 134 · Phase 3 · secondary NCT02561806
  • 71.4% vs 7.7% 150 mg · wk 12 · n 28 · Phase 2 · secondary NCT01107457
  • 72.4% vs 7.7% 75 mg · wk 12 · n 29 · Phase 2 · secondary NCT01107457
  • 70% vs 7.7% 25 mg · wk 12 · n 30 · Phase 2 · secondary NCT01107457
  • 25% vs 7.7% 10 mg · wk 12 · n 28 · Phase 2 · secondary NCT01107457
62.5% vs 2.8%+59.7 vs placebo300mg · wk 12 · n 323NCT01358578
3 other results
  • 51.1% vs 2.8% 150mg · wk 12 · n 327 · Phase 3 · primary NCT01358578
  • 62.5% vs 27.2% 300mg · wk 12 · n 323 · Phase 3 · secondary NCT01358578
  • 51.1% vs 27.2% 150mg · wk 12 · n 327 · Phase 3 · secondary NCT01358578
DLQI, change-9.6 vs -1.7−7.9 vs placebo80 mg every 4 weeks · wk 12 · n 375NCT01646177
12 other results
  • -10.2 vs -1.7 80 mg every 2 weeks · wk 12 · n 377 · Phase 3 · secondary NCT01646177
  • -8.6 vs 0.9 80 mg Q4W · wk 12 · n 170 · Phase 3 · secondary NCT03364309
  • -8.9 vs 0.9 80 mg Q2W · wk 12 · n 175 · Phase 3 · secondary NCT03364309
  • -10.7 vs -1 Q4W · wk 12 · n 421 · Phase 3 · secondary NCT01474512
  • -11.1 vs -1 Q2W · wk 12 · n 427 · Phase 3 · secondary NCT01474512
  • -9.4 vs -2 Q4W · wk 12 · n 338 · Phase 3 · secondary NCT01597245
  • -10.4 vs -2 Q2W · wk 12 · n 343 · Phase 3 · secondary NCT01597245
  • -9.7 vs -1.4 Q2W · wk 12 · n 74 · Phase 3 · secondary NCT02718898
  • -8.2 vs -1.2 150 mg · wk 16 · n 28 · Phase 2 · secondary NCT01107457
  • -8.4 vs -1.2 75 mg · wk 16 · n 29 · Phase 2 · secondary NCT01107457
  • -6.6 vs -1.2 25 mg · wk 16 · n 29 · Phase 2 · secondary NCT01107457
  • -6.3 vs -1.2 10 mg · wk 16 · n 28 · Phase 2 · secondary NCT01107457
-13.2 vs -2.0−11.2 vs placebo300 mg · wk 12 · n 41NCT03589885
1 other result
  • -9.4 vs -0.5 wk 12 · n 46 · Phase 4 · secondary NCT02690701

PASI 75

ixekizumab
84.2% vs 7.3%+76.9 vs placebo80 mg every 4 weeks · wk 12 · n 386NCT01646177
16 other results
  • 87.3% vs 7.3% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · primary NCT01646177
  • 87.4% vs 8% 80 mg Q4W · wk 12 · n 174 · Phase 3 · primary NCT03364309
  • 93.8% vs 8% 80 mg Q2W · wk 12 · n 176 · Phase 3 · primary NCT03364309
  • 82.6% vs 3.9% Q4W · wk 12 · n 432 · Phase 3 · primary NCT01474512
  • 89.1% vs 3.9% Q2W · wk 12 · n 433 · Phase 3 · primary NCT01474512
  • 77.5% vs 2.4% Q4W · wk 12 · n 347 · Phase 3 · primary NCT01597245
  • 89.7% vs 2.4% Q2W · wk 12 · n 351 · Phase 3 · primary NCT01597245
  • 88.7% vs 25% wk 12 · n 115 · Phase 3 · primary NCT03073200
  • 53.9% vs 8.9% wk 4 · n 115 · Phase 3 · secondary NCT03073200
  • 84.2% vs 26.3% wk 12 · n 38 · Phase 3 · secondary NCT03073200
  • 88.2% vs 68.7% wk 12 · n 136 · Phase 3 · secondary NCT02561806
  • 82.1% vs 7.7% 150 mg · wk 12 · n 28 · Phase 2 · primary NCT01107457
  • 82.8% vs 7.7% 75 mg · wk 12 · n 29 · Phase 2 · primary NCT01107457
  • 76.7% vs 7.7% 25 mg · wk 12 · n 30 · Phase 2 · primary NCT01107457
  • 28.6% vs 7.7% 10 mg · wk 12 · n 28 · Phase 2 · primary NCT01107457
  • 22.9% vs 5.1% wk 2 · n 520 · Phase 4 · secondary NCT03573323
secukinumab
77.1% vs 4.9%+72.2 vs placebo300mg · wk 12 · n 323NCT01358578
27 other results
  • 81.6% vs 4.5% 300 mg · wk 12 · n 245 · Phase 3 · primary NCT01365455
  • 93.4% vs 4.4% 300 mg · wk 12 · n 272 · Phase 3 · primary NCT03066609
  • 67% vs 4.9% 150mg · wk 12 · n 327 · Phase 3 · primary NCT01358578
  • 71.6% vs 4.5% 150 mg · wk 12 · n 243 · Phase 3 · primary NCT01365455
  • 75.9% vs 0% 300 mg · wk 12 · n 58 · Phase 3 · primary NCT01555125
  • 82.4% vs 4.4% 150 mg · wk 12 · n 136 · Phase 3 · primary NCT03066609
  • 95.1% vs 10% 300 mg · wk 12 · n 41 · Phase 3 · primary NCT03589885
  • 69.5% vs 0% 150 mg · wk 12 · n 59 · Phase 3 · primary NCT01555125
  • 88.9% vs 1.4% 2 mL PFS · wk 12 · n 72 · Phase 3 · primary NCT02748863
  • 80% vs 14.6% low dose · wk 12 · n 40 · Phase 3 · primary NCT02471144
  • 77.5% vs 14.6% high dose · wk 12 · n 40 · Phase 3 · primary NCT02471144
  • 64.7% vs 2% wk 12 · n 51 · Phase 3 · secondary NCT02267135
  • 77.1% vs 44% 300mg · wk 12 · n 323 · Phase 3 · secondary NCT01358578
  • 88% vs 74.1% 300 mg · wk 12 · n 550 · Phase 3 · secondary NCT02826603
  • 92% vs 79.9% 300 mg · wk 16 · n 550 · Phase 3 · secondary NCT02826603
  • 40.2% vs 16.3% 300 mg · wk 4 · n 550 · Phase 3 · secondary NCT02826603
  • 49.7% vs 20.6% 300 mg · wk 4 · n 334 · Phase 3 · secondary NCT02074982
  • 67% vs 44% 150mg · wk 12 · n 327 · Phase 3 · secondary NCT01358578
  • 87.6% vs 21.1% wk 12 · n 105 · Phase 3 · secondary NCT02474082
  • 80% vs 8.4% wk 8 · n 105 · Phase 3 · secondary NCT02474082
  • 88.6% vs 27.4% wk 16 · n 105 · Phase 3 · secondary NCT02474082
  • 69.5% vs 2.1% wk 6 · n 105 · Phase 3 · secondary NCT02474082
  • 47.6% vs 1.1% wk 4 · n 105 · Phase 3 · secondary NCT02474082
  • 24.8% vs 0% wk 3 · n 105 · Phase 3 · secondary NCT02474082
  • 5.7% vs 0% wk 2 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 1 · n 105 · Phase 3 · secondary NCT02474082
  • 84.8% vs 0% wk 12 · n 46 · Phase 4 · secondary NCT02690701

PASI 90

ixekizumab
72.8% vs 42.2%vs Ustekinumabwk 12 · n 136NCT02561806
9 other results
  • 65.3% vs 3.1% 80 mg every 4 weeks · wk 12 · n 386 · Phase 3 · secondary NCT01646177
  • 68.1% vs 3.1% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · secondary NCT01646177
  • 75.9% vs 2.3% 80 mg Q4W · wk 12 · n 174 · Phase 3 · secondary NCT03364309
  • 82.4% vs 2.3% 80 mg Q2W · wk 12 · n 176 · Phase 3 · secondary NCT03364309
  • 59.7% vs 0.6% Q4W · wk 12 · n 347 · Phase 3 · secondary NCT01597245
  • 70.7% vs 0.6% Q2W · wk 12 · n 351 · Phase 3 · secondary NCT01597245
  • 78.3% vs 5.4% wk 12 · n 115 · Phase 3 · secondary NCT03073200
  • 58.5% vs 35.9% wk 8 · n 520 · Phase 4 · secondary NCT03573323
  • 21% vs 7.9% wk 4 · n 520 · Phase 4 · secondary NCT03573323
secukinumab
66.5% vs 48%vs Ustekinumab300 mg · wk 12 · n 550NCT02826603
23 other results
  • 79% vs 57.3% 300 mg · wk 16 · n 334 · Phase 3 · primary NCT02074982
  • 54.2% vs 1.5% 300mg · wk 12 · n 323 · Phase 3 · secondary NCT01358578
  • 59.2% vs 1.2% 300 mg · wk 12 · n 245 · Phase 3 · secondary NCT01365455
  • 77.2% vs 1.5% 300 mg · wk 12 · n 272 · Phase 3 · secondary NCT03066609
  • 41.9% vs 1.5% 150mg · wk 12 · n 327 · Phase 3 · secondary NCT01358578
  • 39.1% vs 1.2% 150 mg · wk 12 · n 243 · Phase 3 · secondary NCT01365455
  • 62.5% vs 1.5% 150 mg · wk 12 · n 136 · Phase 3 · secondary NCT03066609
  • 75.6% vs 5% 300 mg · wk 12 · n 41 · Phase 3 · secondary NCT03589885
  • 47.1% vs 0% wk 12 · n 51 · Phase 3 · secondary NCT02267135
  • 66.7% vs 1.4% 2 mL PFS · wk 12 · n 72 · Phase 3 · secondary NCT02748863
  • 72.5% vs 2.4% low dose · wk 12 · n 40 · Phase 3 · secondary NCT02471144
  • 67.5% vs 2.4% high dose · wk 12 · n 40 · Phase 3 · secondary NCT02471144
  • 76.9% vs 54.2% 300 mg · wk 16 · n 550 · Phase 3 · secondary NCT02826603
  • 63.8% vs 2.1% wk 12 · n 105 · Phase 3 · secondary NCT02474082
  • 46.7% vs 1.1% wk 8 · n 105 · Phase 3 · secondary NCT02474082
  • 68.6% vs 8.4% wk 16 · n 105 · Phase 3 · secondary NCT02474082
  • 32.4% vs 0% wk 6 · n 105 · Phase 3 · secondary NCT02474082
  • 17.1% vs 0% wk 4 · n 105 · Phase 3 · secondary NCT02474082
  • 2.9% vs 0% wk 3 · n 105 · Phase 3 · secondary NCT02474082
  • 1.9% vs 0% wk 2 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 1 · n 105 · Phase 3 · secondary NCT02474082
  • 53.7% vs 0% 300 mg · wk 12 · n 54 · Phase 4 · primary NCT03055494
  • 73.9% vs 0% wk 12 · n 46 · Phase 4 · secondary NCT02690701

PASI 100

ixekizumab
35% vs 0%+35 vs placebo80 mg every 4 weeks · wk 12 · n 386NCT01646177
10 other results
  • 37.7% vs 0% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · secondary NCT01646177
  • 29.3% vs 0% 80 mg Q4W · wk 12 · n 174 · Phase 3 · secondary NCT03364309
  • 33% vs 0% 80 mg Q2W · wk 12 · n 176 · Phase 3 · secondary NCT03364309
  • 30.8% vs 0.6% Q4W · wk 12 · n 347 · Phase 3 · secondary NCT01597245
  • 40.5% vs 0.6% Q2W · wk 12 · n 351 · Phase 3 · secondary NCT01597245
  • 49.6% vs 1.8% wk 12 · n 115 · Phase 3 · secondary NCT03073200
  • 36% vs 14.5% wk 12 · n 136 · Phase 3 · secondary NCT02561806
  • 41.3% vs 24.9% wk 12 · n 520 · Phase 4 · primary NCT03573323
  • 29.6% vs 13.6% wk 8 · n 520 · Phase 4 · secondary NCT03573323
  • 6.7% vs 1.4% wk 4 · n 520 · Phase 4 · secondary NCT03573323
secukinumab
23.5% vs 0%+23.5 vs placebowk 12 · n 51NCT02267135
13 other results
  • 38.9% vs 0% 2 mL PFS · wk 12 · n 72 · Phase 3 · secondary NCT02748863
  • 36.6% vs 0% 2 x 1 mL PFS · wk 12 · n 71 · Phase 3 · secondary NCT02748863
  • 38.2% vs 20.1% 300 mg · wk 12 · n 550 · Phase 3 · secondary NCT02826603
  • 45.5% vs 26.6% 300 mg · wk 16 · n 550 · Phase 3 · secondary NCT02826603
  • 28.6% vs 0% wk 12 · n 105 · Phase 3 · secondary NCT02474082
  • 15.2% vs 0% wk 8 · n 105 · Phase 3 · secondary NCT02474082
  • 37.1% vs 0% wk 16 · n 105 · Phase 3 · secondary NCT02474082
  • 7.6% vs 0% wk 6 · n 105 · Phase 3 · secondary NCT02474082
  • 3.8% vs 0% wk 4 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 3 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 2 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 1 · n 105 · Phase 3 · secondary NCT02474082
  • 37% vs 0% wk 12 · n 46 · Phase 4 · secondary NCT02690701

sPGA 0/1

ixekizumab
75.4% vs 6.7%+68.7 vs placebo80 mg every 4 weeks · wk 12 · n 386NCT01646177
16 other results
  • 80.5% vs 6.7% 80 mg every 2 weeks · wk 12 · n 385 · Phase 3 · primary NCT01646177
  • 79.9% vs 3.4% 80 mg Q4W · wk 12 · n 174 · Phase 3 · primary NCT03364309
  • 86.4% vs 3.4% 80 mg Q2W · wk 12 · n 176 · Phase 3 · primary NCT03364309
  • 76.4% vs 3.2% Q4W · wk 12 · n 432 · Phase 3 · primary NCT01474512
  • 81.8% vs 3.2% Q2W · wk 12 · n 433 · Phase 3 · primary NCT01474512
  • 72.9% vs 2.4% Q4W · wk 12 · n 347 · Phase 3 · primary NCT01597245
  • 83.2% vs 2.4% Q2W · wk 12 · n 351 · Phase 3 · primary NCT01597245
  • 80.9% vs 10.7% wk 12 · n 115 · Phase 3 · primary NCT03073200
  • 73.3% vs 2.7% 80mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT02718898
  • 47.8% vs 7.1% wk 4 · n 115 · Phase 3 · secondary NCT03073200
  • 76.3% vs 5.3% wk 12 · n 38 · Phase 3 · secondary NCT03073200
  • 83.6% vs 57.2% wk 12 · n 134 · Phase 3 · secondary NCT02561806
  • 71.4% vs 7.7% 150 mg · wk 12 · n 28 · Phase 2 · secondary NCT01107457
  • 72.4% vs 7.7% 75 mg · wk 12 · n 29 · Phase 2 · secondary NCT01107457
  • 70% vs 7.7% 25 mg · wk 12 · n 30 · Phase 2 · secondary NCT01107457
  • 25% vs 7.7% 10 mg · wk 12 · n 28 · Phase 2 · secondary NCT01107457
secukinumab
62.5% vs 2.8%+59.7 vs placebo300mg · wk 12 · n 323NCT01358578
3 other results
  • 51.1% vs 2.8% 150mg · wk 12 · n 327 · Phase 3 · primary NCT01358578
  • 62.5% vs 27.2% 300mg · wk 12 · n 323 · Phase 3 · secondary NCT01358578
  • 51.1% vs 27.2% 150mg · wk 12 · n 327 · Phase 3 · secondary NCT01358578

DLQI, change

ixekizumab
-9.6 vs -1.7−7.9 vs placebo80 mg every 4 weeks · wk 12 · n 375NCT01646177
12 other results
  • -10.2 vs -1.7 80 mg every 2 weeks · wk 12 · n 377 · Phase 3 · secondary NCT01646177
  • -8.6 vs 0.9 80 mg Q4W · wk 12 · n 170 · Phase 3 · secondary NCT03364309
  • -8.9 vs 0.9 80 mg Q2W · wk 12 · n 175 · Phase 3 · secondary NCT03364309
  • -10.7 vs -1 Q4W · wk 12 · n 421 · Phase 3 · secondary NCT01474512
  • -11.1 vs -1 Q2W · wk 12 · n 427 · Phase 3 · secondary NCT01474512
  • -9.4 vs -2 Q4W · wk 12 · n 338 · Phase 3 · secondary NCT01597245
  • -10.4 vs -2 Q2W · wk 12 · n 343 · Phase 3 · secondary NCT01597245
  • -9.7 vs -1.4 Q2W · wk 12 · n 74 · Phase 3 · secondary NCT02718898
  • -8.2 vs -1.2 150 mg · wk 16 · n 28 · Phase 2 · secondary NCT01107457
  • -8.4 vs -1.2 75 mg · wk 16 · n 29 · Phase 2 · secondary NCT01107457
  • -6.6 vs -1.2 25 mg · wk 16 · n 29 · Phase 2 · secondary NCT01107457
  • -6.3 vs -1.2 10 mg · wk 16 · n 28 · Phase 2 · secondary NCT01107457
secukinumab
-13.2 vs -2.0−11.2 vs placebo300 mg · wk 12 · n 41NCT03589885
1 other result
  • -9.4 vs -0.5 wk 12 · n 46 · Phase 4 · secondary NCT02690701
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
27 other shared endpoints and safety

Coverage. ixekizumab: 31 of 31 rows · secukinumab: 31 of 31 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricixekizumab
Rows use multiple source trials
secukinumab
Rows use multiple source trials
BSA Involvement
absolute value · percentage points
Induction
-22.4% (n=428) vs 1.3% (n=426) placebo @ 12wkQ2Wa,b,c
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 1 more dose
-21.4% (n=425) vs 1.3% (n=426) placebo @ 12wkQ4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
5.2% (n=105) vs 13.7% (n=95) Fumaric Acid @ 12wkb,c
NCT02474082 · Phase 3 · registry result, not featured evidence
DLQI
absolute change · score
Maintenance
-13.08 vs -5.37 Fumaric Acid Esters score @ 24wkb,c,d
NCT02634801 · Phase 3 · registry result, not featured evidence
-12.44 vs -14.33 placebo score @ 52wk300 mgb,c,d
NCT03589885 · Phase 3
1 other source trial
-10 vs -9.72 placebo score @ 52wk
NCT02409667 · Phase 3 · registry result, not featured evidence
DLQI
absolute change · score
No placebo or comparator arm
-9.6 score @ 52wk80 mgb,c
NCT01624233 · Phase 3 · registry result, not featured evidence
3 other source trials
-10.23 score @ 52wk80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
-9.7 score @ 52wk80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
-9.97 score @ 52wk80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
-12.7 score @ 52wka,b,c
NCT02409667 · Phase 3 · registry result, not featured evidence
show 1 more dose
-11.4 score @ 52wk
NCT02409667 · Phase 3 · registry result, not featured evidence
DLQI 0/1
responder rate · % of participants
Induction
61% (n=136) vs 44.6% (n=166) Ustekinumab @ 12wkb,c
NCT02561806 · Phase 3 · registry result, not featured evidence
58.8% (n=245) vs 10.3% (n=247) placebo @ 12wk300 mga,b,c
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
show 1 more dose
46.1% (n=245) vs 10.3% (n=247) placebo @ 12wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
DLQI 0/1
responder rate · % of participants
Maintenance
63% (n=54) vs 14.8% (n=54) Fumaric Acid Esters @ 24wkb,c
NCT02634801 · Phase 3 · registry result, not featured evidence
64.6% (n=245) vs 50% (n=18) placebo @ 24wk300 mga,b,c
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
show 3 more doses
67.3% (n=105) vs 50% (n=18) placebo @ 24wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
54.7% (n=245) vs 50% (n=18) placebo @ 24wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
53.7% (n=108) vs 50% (n=18) placebo @ 24wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
DLQI 0/1
responder rate · % of participants
No placebo or comparator arm
74% (n=611) @ 52wk80 mg Q2Wa,b,c,e
NCT02513550 · Phase 3 · registry result, not featured evidence
show 2 more doses
66.1% (n=310) @ 52wk80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
70.3% (n=306) @ 52wk80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
58.9% (n=163) @ 32wk*300 mg s.c. (2-weekly)a,b,c,e
NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 96 participants with DLQI score 0/1 as posted
show 1 more dose
50.6% (n=162) @ 32wk*300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 82 participants with DLQI score 0/1 as posted
Itch NRS
absolute change · score
No placebo or comparator arm
-4.9 score @ 192wk80 mgf,b,c,g
NCT01624233 · Phase 3 · registry result, not featured evidence
3 score @ 4wkf,b,c,g
NCT04717466 · Phase 4 · registry result, not featured evidence
PASI
percent change · % of baseline
Induction
87.12% (n=26) vs 16.22% (n=23) placebo @ 12wk150 mga,h,b,c
NCT01107457 · Phase 2 · registry result, not featured evidence
show 3 more doses
85.69% (n=29) vs 16.22% (n=23) placebo @ 12wk75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
78.48% (n=29) vs 16.22% (n=23) placebo @ 12wk25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
49.33% (n=27) vs 16.22% (n=23) placebo @ 12wk10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-87.72% (n=245) vs -5.89% (n=247) placebo @ 12wk300 mga,h,b,c
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
show 1 more dose
-80.87% (n=245) vs -5.89% (n=247) placebo @ 12wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
PASI
absolute change · score
Induction
15.38 vs 3.5 placebo score @ 12wk150 mga,h,b,c
NCT01107457 · Phase 2 · registry result, not featured evidence
show 3 more doses
14.99 vs 3.5 placebo score @ 12wk75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
13.56 vs 3.5 placebo score @ 12wk25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
8.2 vs 3.5 placebo score @ 12wk10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-17.9 vs 0.5 placebo score @ 12wk300 mga,h,b,c
NCT01555125 · Phase 3
show 1 more dose
-16.33 vs 0.5 placebo score @ 12wk150 mg
NCT01555125 · Phase 3
PASI
absolute change · score
Maintenance
-16.68 vs -4.93 Fumaric Acid Esters score @ 24wkb,c,d
NCT02634801 · Phase 3 · registry result, not featured evidence
-25.75 vs -21.16 Etanercept score @ 52wkhigh dosea,b,c,d
NCT02471144 · Phase 3
show 1 more dose
-25.26 vs -21.16 Etanercept score @ 52wklow dose
NCT02471144 · Phase 3
PASI
absolute change · score
No placebo or comparator arm
-19.41 score @ 52wk80 mg Q2Wa,b,c
NCT02513550 · Phase 3 · registry result, not featured evidence
show 2 more doses
-18.34 score @ 52wk80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
-18.95 score @ 52wk80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
-18.7 score @ 52wk300 mga,b,c
NCT01555125 · Phase 3
show 1 more dose
-16.9 score @ 52wk150 mg
NCT01555125 · Phase 3
PASI
percent change · % of baseline
No placebo or comparator arm
96.25% (n=538) @ 52wk80 mg Q2Wa,f,b,c,i
NCT02513550 · Phase 3 · registry result, not featured evidence
show 2 more doses
91.09% (n=274) @ 52wk80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
94.24% (n=268) @ 52wk80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
-65.64% (n=34) @ 4wk300 mgf,b,c,i
NCT02547714 · Phase 4 · registry result, not featured evidence
PASI 100
responder rate · % of participants
Induction
PASI 100
40.7% (n=59) vs 1.5% (n=67) placebo @ 12wkQ2Wa,j,c
NCT01695239 · Phase 3
show 1 more dose
31.5% (n=73) vs 1.5% (n=67) placebo @ 12wkQ4W
NCT01695239 · Phase 3
26.7% (n=60) vs 0% (n=61) placebo @ 12wk300 mga,j,c
NCT01636687 · Phase 3
show 1 more dose
16.7% (n=61) vs 0% (n=61) placebo @ 12wk150 mg
NCT01636687 · Phase 3
PASI 100
responder rate · % of participants
Maintenance
50% (n=520) vs 52.3% (n=507) Guselkumab @ 24wkk,b,c
NCT03573323 · Phase 4 · registry result, not featured evidence
1 other source trial
40.7% (n=54) vs 3.7% (n=54) Fumaric Acid Esters @ 24wk
NCT02634801 · Phase 3 · registry result, not featured evidence
43.8% (n=105) vs 3.2% (n=95) Fumaric Acid @ 24wkk,b,c
NCT02474082 · Phase 3 · registry result, not featured evidence
PASI 50
responder rate · % of participants
Induction
27.5% (n=520) vs 9.3% (n=507) Guselkumab @ 1wkk,b,c
NCT03573323 · Phase 4 · registry result, not featured evidence
9.5% (n=105) vs 1.1% (n=95) Fumaric Acid @ 1wkk,b,c
NCT02474082 · Phase 3 · registry result, not featured evidence
PASI 75
responder rate · % of participants
Induction
PASI 75
69.5% (n=59) vs 7.5% (n=67) placebo @ 12wkQ2Wa,j,c
NCT01695239 · Phase 3
show 1 more dose
75.3% (n=73) vs 7.5% (n=67) placebo @ 12wkQ4W
NCT01695239 · Phase 3
86.7% (n=60) vs 3.3% (n=61) placebo @ 12wk300 mga,j,c
NCT01636687 · Phase 3
show 1 more dose
71.7% (n=60) vs 3.3% (n=61) placebo @ 12wk150 mg
NCT01636687 · Phase 3
PASI 75
responder rate · % of participants
Maintenance
90.7% (n=54) vs 22.2% (n=54) Fumaric Acid Esters @ 24wkb,c
NCT02634801 · Phase 3 · registry result, not featured evidence
89.52% (n=105) vs 33.68% (n=95) Fumaric Acid @ 24wkb,c
NCT02474082 · Phase 3 · registry result, not featured evidence
PASI 75
responder rate · % of participants
Maintenance
PASI 75
80.4% (n=49) vs 10.9% (n=38) placebo @ 24wkQ2Wa,j,c,d
NCT01695239 · Phase 3
show 1 more dose
71.2% (n=60) vs 10.9% (n=38) placebo @ 24wkQ4W
NCT01695239 · Phase 3
71.2% (n=104) vs 88.9% (n=90) placebo @ 52wk*j,c,d
PASI 75
NCT02409667 · Phase 3 · registry result, not featured evidence · converted to % from 74 Participants as posted
PASI 75
responder rate · % of participants
No placebo or comparator arm
95.9% (n=78) @ 24wk80 mgb,c
NCT01624233 · Phase 3 · registry result, not featured evidence
61.7% (n=107) @ 24wk300 mga,b,c
NCT01961609 · Phase 3 · registry result, not featured evidence
show 2 more doses
68.2% (n=66) @ 24wk150 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
13.5% (n=37) @ 24wk150 mg - 300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
PASI 90
responder rate · % of participants
Induction
PASI 90
57.6% (n=59) vs 1.5% (n=67) placebo @ 12wkQ2Wa,j,c
NCT01695239 · Phase 3
show 1 more dose
52.1% (n=73) vs 1.5% (n=67) placebo @ 12wkQ4W
NCT01695239 · Phase 3
55% (n=60) vs 0% (n=61) placebo @ 12wk300 mga,j,c
NCT01636687 · Phase 3
show 1 more dose
40% (n=61) vs 0% (n=61) placebo @ 12wk150 mg
NCT01636687 · Phase 3
PASI 90
responder rate · % of participants
Maintenance
79.6% (n=54) vs 9.3% (n=54) Fumaric Acid Esters @ 24wkb,c
NCT02634801 · Phase 3 · registry result, not featured evidence
75.2% (n=105) vs 18.9% (n=95) Fumaric Acid @ 24wkb,c
NCT02474082 · Phase 3 · registry result, not featured evidence
PASI 90
responder rate · % of participants
No placebo or comparator arm
79.5% (n=611) @ 52wk80 mg Q2Wa,f,b,c
NCT02513550 · Phase 3 · registry result, not featured evidence
show 2 more doses
65.2% (n=310) @ 52wk80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
73.9% (n=306) @ 52wk80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
57.4% (n=54) @ 52wk*300 mgf,b,c
NCT03055494 · Phase 4 · registry result, not featured evidence · converted to % from 31 Participants as posted
PPASI
absolute change · score
Induction
-5.11 vs 6.89 placebo score @ 12wkb,c
NCT03073200 · Phase 3
7 other source trials
-7.78 vs -2.99 placebo score @ 12wk80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
-6.34 vs -2.99 placebo score @ 12wk80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
-10.31 vs -8.34 Ustekinumab score @ 12wk
NCT02561806 · Phase 3 · registry result, not featured evidence
-6.4 vs -1 placebo score @ 12wk10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-12.8 vs -1 placebo score @ 12wk150 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-4.6 vs -1 placebo score @ 12wk25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-3.4 vs -1 placebo score @ 12wk75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-12.83 vs -3.07 placebo score @ 12wk300 mga,b,c
NCT01806597 · Phase 3 · registry result, not featured evidence
show 1 more dose
-10.15 vs -3.07 placebo score @ 12wk150 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
PPASI
absolute change · score
Maintenance
-7.23 vs -2.45 Fumaric Acid Esters score @ 24wkb,c,l
NCT02634801 · Phase 3 · registry result, not featured evidence
-17.43 vs -11.4 placebo score @ 32wk300 mga,b,c,l
NCT01806597 · Phase 3 · registry result, not featured evidence
show 1 more dose
-16.29 vs -11.4 placebo score @ 32wk150 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
PPASI
absolute change · score
No placebo or comparator arm
-9 score @ 52wk80 mg Q2Wa,b,c,m
NCT02513550 · Phase 3 · registry result, not featured evidence
show 2 more doses
-9.55 score @ 52wk80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
-9.37 score @ 52wk80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
-19.16 score @ 132wk300 mga,b,c,m
NCT01806597 · Phase 3 · registry result, not featured evidence
show 1 more dose
-16.74 score @ 132wk150 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
PPASI 75
responder rate · % of participants
Induction
75% (n=96) vs 35.2% (n=54) placebo @ 12wk*80 mg every 2 weeksa,b,c
NCT01646177 · Phase 3 · converted to % from 72 Participants as posted
show 1 more dose
79.3% (n=87) vs 35.2% (n=54) placebo @ 12wk*80 mg every 4 weeks
NCT01646177 · Phase 3 · converted to % from 69 Participants as posted
23.9% (n=79) vs 10.1% (n=78) placebo @ 12wk300 mga,b,c
NCT02008890 · Phase 3 · registry result, not featured evidence
show 1 more dose
14.7% (n=80) vs 10.1% (n=78) placebo @ 12wk150 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
PSSI
absolute change · score
Induction
-19.2 vs -1.8 placebo score @ 12wkQ2Wa,b,c
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 1 more dose
-18.3 vs -1.8 placebo score @ 12wkQ4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
-25.47 vs -5.98 placebo score @ 12wkb,c
NCT02267135 · Phase 3
Dropout rate
—Ixe Long-Term Extensionn
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 93 more results
4.2%Q2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
5.6%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q12W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Placebo Long-Term Extension
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Total Ixe Long-Term Extension
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Ixe Long-Term Extension
NCT01597245 · Phase 3 · Psoriasis · phase 3
2.6%Q2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
5.5%Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—ETN/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
—ETN/IXEQ4W/IXEQ4W (Extension Perio
NCT03073200 · Phase 3
0.9%IXEQ4W (Double-Blinded Treatment P
NCT03073200 · Phase 3
—IXEQ4W (Randomized Withdrawal Peri
NCT03073200 · Phase 3
—IXEQ4W/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
—IXEQ4W/IXEQ4W/IXEQ4W (Extension Pe
NCT03073200 · Phase 3
—IXEQ4W_Re-Treatment (Randomized Wi
NCT03073200 · Phase 3
—PBO/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
—PBO/IXEQ4W/IXEQ4W (Extension Perio
NCT03073200 · Phase 3
—Q2W
NCT01695239 · Phase 3
—Q4W
NCT01695239 · Phase 3
6.8%Q2W
NCT01695239 · Phase 3
9.3%Q4W
NCT01695239 · Phase 3
—Q2W
NCT01695239 · Phase 3
—Q4W
NCT01695239 · Phase 3
5.7%80 mg every 2 weeks
NCT01646177 · Phase 3
6.7%80 mg every 4 weeks
NCT01646177 · Phase 3
6%Ixekizumab - Active PsA
NCT05855967 · Phase 4 · registry result, not featured evidence
6%Ixekizumab - PsO With no Active Ps
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q2W/Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
20%Ixekizumab - Erythrodermic Psorias
NCT03942042 · Phase 4 · registry result, not featured evidence
14.3%Ixekizumab - Generalized Pustular
NCT03942042 · Phase 4 · registry result, not featured evidence
10.6%
NCT03573323 · Phase 4 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
0.6%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
2.3%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT02718898 · Phase 3 · registry result, not featured evidence
7.4%Ixekizumab
NCT02634801 · Phase 3 · registry result, not featured evidence
—Ixekizumab-Extension Period
NCT02634801 · Phase 3 · registry result, not featured evidence
—Ixekizumab-Treatment Period
NCT02634801 · Phase 3 · registry result, not featured evidence
3.7%Ixekizumab
NCT02561806 · Phase 3 · registry result, not featured evidence
—Ixekizumab - Induction
NCT02561806 · Phase 3 · registry result, not featured evidence
—Ixekizumab - Maintenance
NCT02561806 · Phase 3 · registry result, not featured evidence
—Ixekizumab - Post Treatment Follow
NCT02561806 · Phase 3 · registry result, not featured evidence
1.1%80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
12.1%80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
11.6%80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
12.4%80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
0%Q2W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q2W
NCT02387801 · Phase 3 · registry result, not featured evidence
0%Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
7.8%80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
5.9%80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
3.6%150 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
10.3%75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
3.3%25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
25%10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
—80mg Q2W Multiple Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
—80mg Q4W Multiple Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
0%Single Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
—
NCT02993471 · Phase 1 · registry result, not featured evidence · combination
4.6%300mgo
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
show 95 more results
—300mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—300mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
3.7%150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
2.9%300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
6.1%150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
5.1%300 mg
NCT01555125 · Phase 3
—300 mg
NCT01555125 · Phase 3
1.7%150 mg
NCT01555125 · Phase 3
—150 mg
NCT01555125 · Phase 3
0%300 mg
NCT01636687 · Phase 3
—300 mg
NCT01636687 · Phase 3
4.9%150 mg
NCT01636687 · Phase 3
—150 mg
NCT01636687 · Phase 3
—300 mg
NCT02267135 · Phase 3
2%Secukinumab
NCT02267135 · Phase 3
—300 mg (2x1mL PFS)
NCT02748863 · Phase 3
—300 mg (2mL PFS)
NCT02748863 · Phase 3
0%2 mL PFS
NCT02748863 · Phase 3
—2 mL PFS
NCT02748863 · Phase 3
2.8%2 x 1 mL PFS
NCT02748863 · Phase 3
—2 x 1 mL PFS
NCT02748863 · Phase 3
—300 mg
NCT03589885 · Phase 3
0%
NCT04717466 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03020199 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03020199 · Phase 4 · registry result, not featured evidence
18.5%300 mg
NCT03055494 · Phase 4 · registry result, not featured evidence
13.3%
NCT02592018 · Phase 4 · registry result, not featured evidence
—300 mg
NCT02690701 · Phase 4 · registry result, not featured evidence
4.3%Secukinumab
NCT02690701 · Phase 4 · registry result, not featured evidence
0%300 mg
NCT02547714 · Phase 4 · registry result, not featured evidence
—Entire Period - Secukinumab (AIN45
NCT02547714 · Phase 4 · registry result, not featured evidence
—Induction Period - Secukinumab (AI
NCT02547714 · Phase 4 · registry result, not featured evidence
14.3%AIN457 High Dose
NCT03668613 · Phase 3 · registry result, not featured evidence
26.2%AIN457 Low Dose
NCT03668613 · Phase 3 · registry result, not featured evidence
10.3%300 mg every 2 weeks
NCT03504852 · Phase 3 · registry result, not featured evidence
13.3%300 mg every 4 weeks
NCT03504852 · Phase 3 · registry result, not featured evidence
9.7%300 mg every 4 weeks (up-titration)
NCT03504852 · Phase 3 · registry result, not featured evidence
—300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
0.7%300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
1.5%150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence
11.1%300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence
4.7%300 mg
NCT01544595 · Phase 3 · registry result, not featured evidence
13%150 mg
NCT01544595 · Phase 3 · registry result, not featured evidence
7.7%300 mg
NCT02394561 · Phase 3 · registry result, not featured evidence
7%300 mg
NCT02394561 · Phase 3 · registry result, not featured evidence
19%300 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
18.8%150 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
—Treatment Period 2: Group 1
NCT02409667 · Phase 3 · registry result, not featured evidence
—Treatment Period 2: Group 2
NCT02409667 · Phase 3 · registry result, not featured evidence
—Treatment Period 2: Group 3
NCT02409667 · Phase 3 · registry result, not featured evidence
25%300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
48.5%300 mg open-label
NCT01640951 · Phase 3 · registry result, not featured evidence
78.3%300 mg as needed
NCT01640951 · Phase 3 · registry result, not featured evidence
16.1%300 mg as needed then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
20%150 mg fixed interval then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
13.7%150 mg as needed then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
81.8%150 mg as needed
NCT01640951 · Phase 3 · registry result, not featured evidence
59.7%150 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02595970 · Phase 3 · registry result, not featured evidence
16.7%Single Arm Secukinumab
NCT02595970 · Phase 3 · registry result, not featured evidence
1.5%300 mg
NCT01807520 · Phase 3 · registry result, not featured evidence · pooled
6%150 mg
NCT01807520 · Phase 3 · registry result, not featured evidence · pooled
7.2%300 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
7.4%150 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
3%300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—
NCT02362789 · Phase 3 · registry result, not featured evidence
10.1%300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
11.2%150 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg - 300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg - 300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
15.1%300 mg
NCT02074982 · Phase 3 · registry result, not featured evidence
5.7%
NCT02474082 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—Ixe Long-Term Extensionn
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 93 more results
2.3%Q2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
2.3%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q12W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Placebo Long-Term Extension
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Total Ixe Long-Term Extension
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Ixe Long-Term Extension
NCT01597245 · Phase 3 · Psoriasis · phase 3
1.1%Q2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
1.4%Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
—ETN/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
—ETN/IXEQ4W/IXEQ4W (Extension Perio
NCT03073200 · Phase 3
—IXEQ4W (Double-Blinded Treatment P
NCT03073200 · Phase 3
—IXEQ4W (Randomized Withdrawal Peri
NCT03073200 · Phase 3
—IXEQ4W/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
—IXEQ4W/IXEQ4W/IXEQ4W (Extension Pe
NCT03073200 · Phase 3
—IXEQ4W_Re-Treatment (Randomized Wi
NCT03073200 · Phase 3
—PBO/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
—PBO/IXEQ4W/IXEQ4W (Extension Perio
NCT03073200 · Phase 3
—Q2W
NCT01695239 · Phase 3
—Q4W
NCT01695239 · Phase 3
2.9%Q2W
NCT01695239 · Phase 3
1.9%Q4W
NCT01695239 · Phase 3
—Q2W
NCT01695239 · Phase 3
—Q4W
NCT01695239 · Phase 3
2.1%80 mg every 2 weeks
NCT01646177 · Phase 3
2.3%80 mg every 4 weeks
NCT01646177 · Phase 3
—Ixekizumab - Active PsA
NCT05855967 · Phase 4 · registry result, not featured evidence
—Ixekizumab - PsO With no Active Ps
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q2W/Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
—Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
20%Ixekizumab - Erythrodermic Psorias
NCT03942042 · Phase 4 · registry result, not featured evidence
0%Ixekizumab - Generalized Pustular
NCT03942042 · Phase 4 · registry result, not featured evidence
2.9%
NCT03573323 · Phase 4 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
0.6%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
0%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT02718898 · Phase 3 · registry result, not featured evidence
3.7%Ixekizumab
NCT02634801 · Phase 3 · registry result, not featured evidence
—Ixekizumab-Extension Period
NCT02634801 · Phase 3 · registry result, not featured evidence
—Ixekizumab-Treatment Period
NCT02634801 · Phase 3 · registry result, not featured evidence
1.5%Ixekizumab
NCT02561806 · Phase 3 · registry result, not featured evidence
—Ixekizumab - Induction
NCT02561806 · Phase 3 · registry result, not featured evidence
—Ixekizumab - Maintenance
NCT02561806 · Phase 3 · registry result, not featured evidence
—Ixekizumab - Post Treatment Follow
NCT02561806 · Phase 3 · registry result, not featured evidence
1.1%80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
2.8%80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
1.6%80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
4.2%80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q2W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q2W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
1%80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
2%80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
0%75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
3.3%25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
7.1%10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
—80mg Q2W Multiple Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
—80mg Q4W Multiple Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
—Single Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
—
NCT02993471 · Phase 1 · registry result, not featured evidence · combination
1.2%300mgo
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
show 95 more results
—300mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—300mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
0.6%150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
1.2%300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
2%150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
1.7%300 mg
NCT01555125 · Phase 3
—300 mg
NCT01555125 · Phase 3
0%150 mg
NCT01555125 · Phase 3
—150 mg
NCT01555125 · Phase 3
0%300 mg
NCT01636687 · Phase 3
—300 mg
NCT01636687 · Phase 3
1.6%150 mg
NCT01636687 · Phase 3
—150 mg
NCT01636687 · Phase 3
—300 mg
NCT02267135 · Phase 3
—Secukinumab
NCT02267135 · Phase 3
—300 mg (2x1mL PFS)
NCT02748863 · Phase 3
—300 mg (2mL PFS)
NCT02748863 · Phase 3
0%2 mL PFS
NCT02748863 · Phase 3
—2 mL PFS
NCT02748863 · Phase 3
1.4%2 x 1 mL PFS
NCT02748863 · Phase 3
—2 x 1 mL PFS
NCT02748863 · Phase 3
—300 mg
NCT03589885 · Phase 3
—
NCT04717466 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03020199 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03020199 · Phase 4 · registry result, not featured evidence
0%300 mg
NCT03055494 · Phase 4 · registry result, not featured evidence
6.7%
NCT02592018 · Phase 4 · registry result, not featured evidence
—300 mg
NCT02690701 · Phase 4 · registry result, not featured evidence
4.3%Secukinumab
NCT02690701 · Phase 4 · registry result, not featured evidence
—300 mg
NCT02547714 · Phase 4 · registry result, not featured evidence
—Entire Period - Secukinumab (AIN45
NCT02547714 · Phase 4 · registry result, not featured evidence
—Induction Period - Secukinumab (AI
NCT02547714 · Phase 4 · registry result, not featured evidence
4.8%AIN457 High Dose
NCT03668613 · Phase 3 · registry result, not featured evidence
2.4%AIN457 Low Dose
NCT03668613 · Phase 3 · registry result, not featured evidence
2.4%300 mg every 2 weeks
NCT03504852 · Phase 3 · registry result, not featured evidence
5.9%300 mg every 4 weeks
NCT03504852 · Phase 3 · registry result, not featured evidence
6.5%300 mg every 4 weeks (up-titration)
NCT03504852 · Phase 3 · registry result, not featured evidence
—300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
0.7%300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
1.5%150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence
3.1%300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence
0.6%300 mg
NCT01544595 · Phase 3 · registry result, not featured evidence
1%150 mg
NCT01544595 · Phase 3 · registry result, not featured evidence
3.7%300 mg
NCT02394561 · Phase 3 · registry result, not featured evidence
3.8%300 mg
NCT02394561 · Phase 3 · registry result, not featured evidence
10.1%300 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
7.5%150 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
—Treatment Period 2: Group 1
NCT02409667 · Phase 3 · registry result, not featured evidence
—Treatment Period 2: Group 2
NCT02409667 · Phase 3 · registry result, not featured evidence
—Treatment Period 2: Group 3
NCT02409667 · Phase 3 · registry result, not featured evidence
6%300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
9.1%300 mg open-label
NCT01640951 · Phase 3 · registry result, not featured evidence
18.3%300 mg as needed
NCT01640951 · Phase 3 · registry result, not featured evidence
0.9%300 mg as needed then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
4%150 mg fixed interval then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
1.1%150 mg as needed then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
10.9%150 mg as needed
NCT01640951 · Phase 3 · registry result, not featured evidence
10.4%150 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02595970 · Phase 3 · registry result, not featured evidence
4.2%Single Arm Secukinumab
NCT02595970 · Phase 3 · registry result, not featured evidence
0%300 mg
NCT01807520 · Phase 3 · registry result, not featured evidence · pooled
3%150 mg
NCT01807520 · Phase 3 · registry result, not featured evidence · pooled
1.4%300 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
1.5%150 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
1%300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—
NCT02362789 · Phase 3 · registry result, not featured evidence
2.5%300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
4.3%150 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg - 300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg - 300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
4.5%300 mg
NCT02074982 · Phase 3 · registry result, not featured evidence
1.9%
NCT02474082 · Phase 3 · registry result, not featured evidence
Serious AEs
12.7%Ixe Long-Term Extensionn
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 93 more results
1.6%Q2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
2.8%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
3.2%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
10.3%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
4.8%Q12W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
6.1%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
3.8%Placebo Long-Term Extension
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
6.1%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
4.8%Q4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
12.5%Total Ixe Long-Term Extension
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
4.5%Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
10.9%Ixe Long-Term Extension
NCT01597245 · Phase 3 · Psoriasis · phase 3
1.4%Q2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
4.1%Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
2.3%Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
5.3%Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
8.4%Q4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
3.6%ETN/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
0%ETN/IXEQ4W/IXEQ4W (Extension Perio
NCT03073200 · Phase 3
0.9%IXEQ4W (Double-Blinded Treatment P
NCT03073200 · Phase 3
8.8%IXEQ4W (Randomized Withdrawal Peri
NCT03073200 · Phase 3
6.2%IXEQ4W/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
2.9%IXEQ4W/IXEQ4W/IXEQ4W (Extension Pe
NCT03073200 · Phase 3
0%IXEQ4W_Re-Treatment (Randomized Wi
NCT03073200 · Phase 3
5.7%PBO/IXEQ4W (Maintenance Period)
NCT03073200 · Phase 3
0%PBO/IXEQ4W/IXEQ4W (Extension Perio
NCT03073200 · Phase 3
0%Q2W
NCT01695239 · Phase 3
0%Q4W
NCT01695239 · Phase 3
10.4%Q2W
NCT01695239 · Phase 3
15%Q4W
NCT01695239 · Phase 3
5.6%Q2W
NCT01695239 · Phase 3
2.9%Q4W
NCT01695239 · Phase 3
2.3%80 mg every 2 weeks
NCT01646177 · Phase 3
1.6%80 mg every 4 weeks
NCT01646177 · Phase 3
—Ixekizumab - Active PsA
NCT05855967 · Phase 4 · registry result, not featured evidence
—Ixekizumab - PsO With no Active Ps
NCT05855967 · Phase 4 · registry result, not featured evidence
0.5%Q2W/Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
0%Q4W
NCT05855967 · Phase 4 · registry result, not featured evidence
—Ixekizumab - Erythrodermic Psorias
NCT03942042 · Phase 4 · registry result, not featured evidence
—Ixekizumab - Generalized Pustular
NCT03942042 · Phase 4 · registry result, not featured evidence
3.5%
NCT03573323 · Phase 4 · registry result, not featured evidence
4.3%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
2%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
2%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
0%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
4.4%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
0%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
0.6%80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
0%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
5.4%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
2.1%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
0%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
2.3%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
1.9%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
1.1%80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
0%80 mg Q2W
NCT02718898 · Phase 3 · registry result, not featured evidence
—Ixekizumab
NCT02634801 · Phase 3 · registry result, not featured evidence
6.3%Ixekizumab-Extension Period
NCT02634801 · Phase 3 · registry result, not featured evidence
1.9%Ixekizumab-Treatment Period
NCT02634801 · Phase 3 · registry result, not featured evidence
—Ixekizumab
NCT02561806 · Phase 3 · registry result, not featured evidence
1.5%Ixekizumab - Induction
NCT02561806 · Phase 3 · registry result, not featured evidence
5.3%Ixekizumab - Maintenance
NCT02561806 · Phase 3 · registry result, not featured evidence
0%Ixekizumab - Post Treatment Follow
NCT02561806 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
4.4%80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
11.3%80 mg
NCT01624233 · Phase 3 · registry result, not featured evidence
—80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
5.3%80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
0%80 mg Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
0%80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
—80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
5.2%80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
20%80 mg Q4W/Q2W
NCT02513550 · Phase 3 · registry result, not featured evidence
5.2%80 mg Q4W
NCT02513550 · Phase 3 · registry result, not featured evidence
0%80 mg Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q2W
NCT02387801 · Phase 3 · registry result, not featured evidence
0%Q2W
NCT02387801 · Phase 3 · registry result, not featured evidence
—Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
0%Q4W
NCT02387801 · Phase 3 · registry result, not featured evidence
4.9%80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
3.9%80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
2.9%80 mg
NCT01777191 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
0%75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
3.3%25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
3.6%10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
7.1%80mg Q2W Multiple Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
0%80mg Q4W Multiple Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
0%Single Dose
NCT03073213 · Phase 1 · registry result, not featured evidence
0%
NCT02993471 · Phase 1 · registry result, not featured evidence · combination
—300mgo
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
show 95 more results
6.4%300mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
1.2%300mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
5.5%150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
2.1%150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
6.9%300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
5.4%300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
2.1%300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
2.4%300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
6.1%150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
5.4%150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
1.7%150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
1.6%150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01555125 · Phase 3
5.1%300 mg
NCT01555125 · Phase 3
—150 mg
NCT01555125 · Phase 3
1.7%150 mg
NCT01555125 · Phase 3
—300 mg
NCT01636687 · Phase 3
1.7%300 mg
NCT01636687 · Phase 3
—150 mg
NCT01636687 · Phase 3
4.9%150 mg
NCT01636687 · Phase 3
0%300 mg
NCT02267135 · Phase 3
—Secukinumab
NCT02267135 · Phase 3
1.4%300 mg (2x1mL PFS)
NCT02748863 · Phase 3
0%300 mg (2mL PFS)
NCT02748863 · Phase 3
—2 mL PFS
NCT02748863 · Phase 3
—2 mL PFS
NCT02748863 · Phase 3
—2 x 1 mL PFS
NCT02748863 · Phase 3
—2 x 1 mL PFS
NCT02748863 · Phase 3
2.4%300 mg
NCT03589885 · Phase 3
10%
NCT04717466 · Phase 4 · registry result, not featured evidence
5.4%300 mg
NCT03020199 · Phase 4 · registry result, not featured evidence
0%300 mg
NCT03020199 · Phase 4 · registry result, not featured evidence
1.9%300 mg
NCT03055494 · Phase 4 · registry result, not featured evidence
6.7%
NCT02592018 · Phase 4 · registry result, not featured evidence
10.9%300 mg
NCT02690701 · Phase 4 · registry result, not featured evidence
—Secukinumab
NCT02690701 · Phase 4 · registry result, not featured evidence
—300 mg
NCT02547714 · Phase 4 · registry result, not featured evidence
0%Entire Period - Secukinumab (AIN45
NCT02547714 · Phase 4 · registry result, not featured evidence
0%Induction Period - Secukinumab (AI
NCT02547714 · Phase 4 · registry result, not featured evidence
4.8%AIN457 High Dose
NCT03668613 · Phase 3 · registry result, not featured evidence
9.5%AIN457 Low Dose
NCT03668613 · Phase 3 · registry result, not featured evidence
8.5%300 mg every 2 weeks
NCT03504852 · Phase 3 · registry result, not featured evidence
13.4%300 mg every 4 weeks
NCT03504852 · Phase 3 · registry result, not featured evidence
12.9%300 mg every 4 weeks (up-titration)
NCT03504852 · Phase 3 · registry result, not featured evidence
3.3%300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
—300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
3.7%150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
5.3%300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01544595 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01544595 · Phase 3 · registry result, not featured evidence
8.5%300 mg
NCT02394561 · Phase 3 · registry result, not featured evidence
5.4%300 mg
NCT02394561 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
16.5%300 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
11.3%150 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
3.9%Treatment Period 2: Group 1
NCT02409667 · Phase 3 · registry result, not featured evidence
3.8%Treatment Period 2: Group 2
NCT02409667 · Phase 3 · registry result, not featured evidence
3.5%Treatment Period 2: Group 3
NCT02409667 · Phase 3 · registry result, not featured evidence
—300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
—300 mg open-label
NCT01640951 · Phase 3 · registry result, not featured evidence
—300 mg as needed
NCT01640951 · Phase 3 · registry result, not featured evidence
—300 mg as needed then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
—150 mg fixed interval then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
—150 mg as needed then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
—150 mg as needed
NCT01640951 · Phase 3 · registry result, not featured evidence
—150 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
10.8%300 mg
NCT02595970 · Phase 3 · registry result, not featured evidence
—Single Arm Secukinumab
NCT02595970 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01807520 · Phase 3 · registry result, not featured evidence · pooled
—150 mg
NCT01807520 · Phase 3 · registry result, not featured evidence · pooled
—300 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
2.5%300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
4.9%300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
4.1%300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
4.8%
NCT02362789 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
13.4%300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg - 300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg - 300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
12.2%150 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
12.2%300 mg
NCT02074982 · Phase 3 · registry result, not featured evidence
3.8%
NCT02474082 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
n
nasopharyngitis 16.9% (placebo 11.5%)
upper respiratory tract infection 8.4% (placebo 8%)
arthralgia 5.1% (placebo 2.7%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 79 more results
Q2W
nasopharyngitis 11.3% (placebo 11.5%)
injection site reaction 9.7% (placebo 0.9%)
injection site erythema 6.5% (placebo 0%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q4W
nasopharyngitis 10.4% (placebo 11.5%)
injection site reaction 6.3% (placebo 0.9%)
upper respiratory tract infection 4.6% (placebo 8%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q4W
nasopharyngitis 10.6% (placebo 11.5%)
upper respiratory tract infection 5.2% (placebo 8%)
injection site reaction 3.7% (placebo 0.9%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q4W
nasopharyngitis 24.4% (placebo 11.5%)
arthralgia 10.3% (placebo 2.7%)
upper respiratory tract infection 10.3% (placebo 8%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q12W
nasopharyngitis 18.1% (placebo 11.5%)
upper respiratory tract infection 8.8% (placebo 8%)
headache 7% (placebo 2.2%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q4W
nasopharyngitis 22.3% (placebo 11.5%)
upper respiratory tract infection 7.9% (placebo 8%)
arthralgia 5.7% (placebo 2.7%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
nasopharyngitis 15.4% (placebo 11.5%)
influenza 7.7% (placebo 1.8%)
upper respiratory tract infection 7.7% (placebo 8%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q4W
nasopharyngitis 19.7% (placebo 11.5%)
upper respiratory tract infection 13.6% (placebo 8%)
injection site reaction 9.2% (placebo 0.9%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q4W
nasopharyngitis 17.7% (placebo 11.5%)
back pain 9.7% (placebo 3.1%)
upper respiratory tract infection 6.5% (placebo 8%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
nasopharyngitis 16.6% (placebo 11.5%)
upper respiratory tract infection 8.3% (placebo 8%)
arthralgia 5% (placebo 2.7%)
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
Q4W
nasopharyngitis 17.5% (placebo 14.4%)
upper respiratory tract infection 10.5% (placebo 6.1%)
injection site reaction 10% (placebo 0.8%)
NCT01597245 · Phase 3 · Psoriasis · phase 3
nasopharyngitis 12.8% (placebo 14.4%)
upper respiratory tract infection 11% (placebo 6.1%)
arthralgia 4.9% (placebo 6.1%)
NCT01597245 · Phase 3 · Psoriasis · phase 3
Q2W
injection site reaction 11.4% (placebo 0.8%)
nasopharyngitis 9.7% (placebo 14.4%)
upper respiratory tract infection 5.7% (placebo 6.1%)
NCT01597245 · Phase 3 · Psoriasis · phase 3
Q4W
nasopharyngitis 16.3% (placebo 14.4%)
upper respiratory tract infection 14.3% (placebo 6.1%)
headache 8.2% (placebo 3.8%)
NCT01597245 · Phase 3 · Psoriasis · phase 3
Q4W
nasopharyngitis 8.1% (placebo 14.4%)
injection site reaction 5.5% (placebo 0.8%)
headache 4.9% (placebo 3.8%)
NCT01597245 · Phase 3 · Psoriasis · phase 3
Q4W
nasopharyngitis 16% (placebo 14.4%)
upper respiratory tract infection 9.3% (placebo 6.1%)
vulvovaginal candidiasis 9.1% (placebo 0%)
NCT01597245 · Phase 3 · Psoriasis · phase 3
Q4W
nasopharyngitis 18.7% (placebo 14.4%)
upper respiratory tract infection 12.9% (placebo 6.1%)
injection site reaction 6.5% (placebo 0.8%)
NCT01597245 · Phase 3 · Psoriasis · phase 3
nasopharyngitis 14.3% (placebo 7.1%)
pharyngitis 14.3% (placebo 0%)
tonsillitis 14.3% (placebo 3.6%)
NCT03073200 · Phase 3
acne 11.1% (placebo 1.8%)
headache 11.1% (placebo 1.8%)
influenza 11.1% (placebo 0%)
NCT03073200 · Phase 3
nasopharyngitis 11.3% (placebo 7.1%)
headache 10.4% (placebo 1.8%)
injection site reaction 9.6% (placebo 0%)
NCT03073200 · Phase 3
nasopharyngitis 32.4% (placebo 7.1%)
tonsillitis 8.8% (placebo 3.6%)
viral upper respiratory tract infection 8.8% (placebo 0%)
NCT03073200 · Phase 3
injection site reaction 17.7% (placebo 0%)
nasopharyngitis 14.2% (placebo 7.1%)
upper respiratory tract infection 11.5% (placebo 7.1%)
NCT03073200 · Phase 3
upper respiratory tract infection 16.2% (placebo 7.1%)
nasopharyngitis 11.8% (placebo 7.1%)
headache 8.8% (placebo 1.8%)
NCT03073200 · Phase 3
diarrhoea 6.1% (placebo 1.8%)
nasopharyngitis 6.1% (placebo 7.1%)
pharyngitis 6.1% (placebo 0%)
NCT03073200 · Phase 3
injection site reaction 15.1% (placebo 0%)
nasopharyngitis 13.2% (placebo 7.1%)
upper respiratory tract infection 9.4% (placebo 7.1%)
NCT03073200 · Phase 3
upper respiratory tract infection 29.4% (placebo 7.1%)
bronchitis 8.8% (placebo 0%)
pharyngitis 8.8% (placebo 0%)
NCT03073200 · Phase 3
Q2W
back pain 0% (placebo 0%)
bronchitis 0% (placebo 2.8%)
injection site erythema 0% (placebo 0%)
NCT01695239 · Phase 3
Q4W
back pain 0% (placebo 0%)
bronchitis 0% (placebo 2.8%)
injection site erythema 0% (placebo 0%)
NCT01695239 · Phase 3
Q2W
viral upper respiratory tract infection 11.5% (placebo 4.7%)
upper respiratory tract infection 9.8% (placebo 6.6%)
injection site reaction 7.1% (placebo 0%)
NCT01695239 · Phase 3
Q4W
upper respiratory tract infection 11.2% (placebo 6.6%)
viral upper respiratory tract infection 11.2% (placebo 4.7%)
injection site reaction 6.4% (placebo 0%)
NCT01695239 · Phase 3
Q2W
injection site reaction 12.1% (placebo 0%)
injection site erythema 6.5% (placebo 0%)
viral upper respiratory tract infection 5.6% (placebo 4.7%)
NCT01695239 · Phase 3
Q4W
injection site reaction 15.7% (placebo 0%)
injection site erythema 12.7% (placebo 0%)
bronchitis 2.9% (placebo 2.8%)
NCT01695239 · Phase 3
80 mg every 2 weeks
injection site reaction 9.6% (placebo 1.6%)
nasopharyngitis 6.8% (placebo 5.7%)
headache 4.2% (placebo 2.6%)
NCT01646177 · Phase 3
80 mg every 4 weeks
injection site reaction 11.3% (placebo 1.6%)
nasopharyngitis 7.6% (placebo 5.7%)
headache 4.2% (placebo 2.6%)
NCT01646177 · Phase 3
Q2W/Q4W
latent tuberculosis 8.6%
pyrexia 8.6%
injection site erythema 1.9%
NCT05855967 · Phase 4 · registry result, not featured evidence
Q4W
latent tuberculosis 9.8%
urinary tract infection 4.9%
c-reactive protein increased 2.4%
NCT05855967 · Phase 4 · registry result, not featured evidence
injection site reaction 9.4%
upper respiratory tract infection 7.7%
nasopharyngitis 6.6%
NCT03573323 · Phase 4 · registry result, not featured evidence
80 mg Q2W
blood glucose increased 17.4% (placebo 6.3%)
folliculitis 13% (placebo 5.1%)
hepatic function abnormal 13% (placebo 5.1%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q2W
upper respiratory tract infection 31% (placebo 27.8%)
injection site reaction 17% (placebo 10.1%)
tinea pedis 10% (placebo 7.6%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q2W
upper respiratory tract infection 12% (placebo 27.8%)
oropharyngeal pain 10% (placebo 2.5%)
blood triglycerides increased 8% (placebo 0%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q2W
alopecia 10% (placebo 0%)
blood immunoglobulin a increased 10% (placebo 1.3%)
blood urine present 10% (placebo 6.3%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q2W
upper respiratory tract infection 20% (placebo 27.8%)
injection site reaction 11.1% (placebo 10.1%)
oropharyngeal pain 11.1% (placebo 2.5%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q2W
alopecia 0% (placebo 0%)
arthralgia 0% (placebo 0%)
blood glucose decreased 0% (placebo 0%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q2W
upper respiratory tract infection 15.9% (placebo 27.8%)
injection site reaction 10.8% (placebo 10.1%)
urticaria 5.7% (placebo 11.4%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 25.8% (placebo 27.8%)
blood urine present 12.9% (placebo 6.3%)
tinea pedis 12.9% (placebo 7.6%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 27.2% (placebo 27.8%)
injection site reaction 18.5% (placebo 10.1%)
tinea pedis 12% (placebo 7.6%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 14.9% (placebo 27.8%)
oropharyngeal pain 8.5% (placebo 2.5%)
pruritus 8.5% (placebo 2.5%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q4W
tonsillitis 28.6% (placebo 0%)
upper respiratory tract infection 28.6% (placebo 27.8%)
dermatitis allergic 14.3% (placebo 5.1%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 16.3% (placebo 27.8%)
injection site reaction 7% (placebo 10.1%)
rhinitis 7% (placebo 1.3%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q4W
hepatic function abnormal 1.3% (placebo 5.1%)
blood glucose increased 1.1% (placebo 6.3%)
upper respiratory tract infection 1.1% (placebo 27.8%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 14.4% (placebo 27.8%)
injection site reaction 7.5% (placebo 10.1%)
hepatic function abnormal 5.7% (placebo 5.1%)
NCT03364309 · Phase 3 · registry result, not featured evidence
80 mg Q2W
upper respiratory tract infection 16% (placebo 6.8%)
injection site reaction 6.7% (placebo 0%)
headache 4% (placebo 5.4%)
NCT02718898 · Phase 3 · registry result, not featured evidence
nasopharyngitis 37.5%
back pain 6.3%
bronchitis 4.2%
NCT02634801 · Phase 3 · registry result, not featured evidence
nasopharyngitis 37%
headache 13%
injection site reaction 13%
NCT02634801 · Phase 3 · registry result, not featured evidence
nasopharyngitis 17%
injection site erythema 7.4%
headache 5.2%
NCT02561806 · Phase 3 · registry result, not featured evidence
nasopharyngitis 27.5%
headache 7.6%
arthralgia 6.1%
NCT02561806 · Phase 3 · registry result, not featured evidence
arthralgia 0%
back pain 0%
headache 0%
NCT02561806 · Phase 3 · registry result, not featured evidence
80 mg
viral upper respiratory tract infection 39.6%
eczema 12.1%
injection site reaction 8.8%
NCT01624233 · Phase 3 · registry result, not featured evidence
80 mg
viral upper respiratory tract infection 20%
eczema 12.5%
eczema asteatotic 11.3%
NCT01624233 · Phase 3 · registry result, not featured evidence
80 mg Q2W
viral upper respiratory tract infection 12%
upper respiratory tract infection 11.3%
injection site reaction 8%
NCT02513550 · Phase 3 · registry result, not featured evidence
80 mg Q2W
viral upper respiratory tract infection 37.5%
vaginal infection 25%
injection site erythema 12.5%
NCT02513550 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 22.2%
alanine aminotransferase increased 11.1%
aspartate aminotransferase increased 11.1%
NCT02513550 · Phase 3 · registry result, not featured evidence
80 mg Q4W/Q2W
viral upper respiratory tract infection 17.3%
upper respiratory tract infection 12.7%
headache 5.2%
NCT02513550 · Phase 3 · registry result, not featured evidence
80 mg Q4W/Q2W
arthralgia 20%
benign bone neoplasm 20%
blood glucose increased 20%
NCT02513550 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 14.8%
viral upper respiratory tract infection 13.2%
injection site reaction 5.8%
NCT02513550 · Phase 3 · registry result, not featured evidence
80 mg Q4W
upper respiratory tract infection 33.3%
biopsy breast 16.7%
influenza 16.7%
NCT02387801 · Phase 3 · registry result, not featured evidence
Q2W
arthralgia 33.3%
acne 16.7%
hyperhidrosis 16.7%
NCT02387801 · Phase 3 · registry result, not featured evidence
Q4W
biopsy prostate 33.3%
injection site urticaria 33.3%
hordeolum 16.7%
NCT02387801 · Phase 3 · registry result, not featured evidence
80 mg
upper respiratory tract infection 8.6%
injection site reaction 4.3%
NCT01777191 · Phase 3 · registry result, not featured evidence
80 mg
injection site reaction 4.9%
upper respiratory tract infection 4.9%
NCT01777191 · Phase 3 · registry result, not featured evidence
80 mg
injection site reaction 7.8%
upper respiratory tract infection 3.9%
NCT01777191 · Phase 3 · registry result, not featured evidence
150 mg
nasopharyngitis 14.3% (placebo 18.5%)
dermatitis contact 7.1% (placebo 0%)
dry skin 7.1% (placebo 0%)
NCT01107457 · Phase 2 · registry result, not featured evidence
75 mg
nasopharyngitis 10.3% (placebo 18.5%)
cough 6.9% (placebo 0%)
dizziness 6.9% (placebo 0%)
NCT01107457 · Phase 2 · registry result, not featured evidence
25 mg
headache 13.3% (placebo 3.7%)
injection site reaction 10% (placebo 0%)
nasopharyngitis 10% (placebo 18.5%)
NCT01107457 · Phase 2 · registry result, not featured evidence
10 mg
headache 14.3% (placebo 3.7%)
nasopharyngitis 10.7% (placebo 18.5%)
dizziness 7.1% (placebo 0%)
NCT01107457 · Phase 2 · registry result, not featured evidence
80mg Q2W Multiple Dose
pruritus 42.9%
upper respiratory tract infection 35.7%
diarrhoea 21.4%
NCT03073213 · Phase 1 · registry result, not featured evidence
80mg Q4W Multiple Dose
upper respiratory tract infection 20%
arthralgia 13.3%
diarrhoea 13.3%
NCT03073213 · Phase 1 · registry result, not featured evidence
Single Dose
pruritus 41.7%
protein urine present 33.3%
flatulence 25%
NCT03073213 · Phase 1 · registry result, not featured evidence
alopecia 3.7%
arthralgia 3.7%
back pain 3.7%
NCT02993471 · Phase 1 · registry result, not featured evidence · combination
300mgo
nasopharyngitis 27.9% (placebo 8%)
headache 14.4% (placebo 7.3%)
diarrhoea 10.4% (placebo 2.1%)
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
show 51 more results
300mg
nasopharyngitis 10.7% (placebo 8%)
headache 9.2% (placebo 7.3%)
diarrhoea 5.2% (placebo 2.1%)
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
150mg
nasopharyngitis 25.1% (placebo 8%)
headache 10.4% (placebo 7.3%)
diarrhoea 9.2% (placebo 2.1%)
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
150mg
nasopharyngitis 13.5% (placebo 8%)
headache 4.9% (placebo 7.3%)
arthralgia 4.3% (placebo 3.1%)
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
300 mg
nasopharyngitis 18.4% (placebo 8.1%)
upper respiratory tract infection 10.6% (placebo 0.8%)
headache 9% (placebo 4%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
300 mg
nasopharyngitis 16.3% (placebo 8.1%)
upper respiratory tract infection 9.2% (placebo 0.8%)
headache 8.6% (placebo 4%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
300 mg
arthralgia 2.1% (placebo 3.2%)
blood creatinine increased 2.1% (placebo 0.4%)
eczema 2.1% (placebo 0%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
300 mg
nasopharyngitis 9% (placebo 8.1%)
headache 4.9% (placebo 4%)
pruritus 4.5% (placebo 2.4%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
150 mg
nasopharyngitis 21.6% (placebo 8.1%)
upper respiratory tract infection 11.4% (placebo 0.8%)
headache 7.8% (placebo 4%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
150 mg
nasopharyngitis 19.5% (placebo 8.1%)
upper respiratory tract infection 10.2% (placebo 0.8%)
headache 6.8% (placebo 4%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
150 mg
psoriasis 3.4% (placebo 3.2%)
psoriatic arthropathy 3.4% (placebo 1.6%)
influenza 1.7% (placebo 1.2%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
150 mg
nasopharyngitis 9.4% (placebo 8.1%)
headache 5.3% (placebo 4%)
oropharyngeal pain 4.1% (placebo 1.2%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
300 mg
diarrhoea 8.5% (placebo 1.7%)
back pain 5.1% (placebo 0%)
nasopharyngitis 5.1% (placebo 8.5%)
NCT01555125 · Phase 3
150 mg
headache 6.8% (placebo 6.8%)
diarrhoea 5.1% (placebo 1.7%)
nasopharyngitis 5.1% (placebo 8.5%)
NCT01555125 · Phase 3
300 mg
nasopharyngitis 31.7% (placebo 14.8%)
pruritus 6.7% (placebo 3.3%)
cough 5% (placebo 3.3%)
NCT01636687 · Phase 3
150 mg
nasopharyngitis 23% (placebo 14.8%)
headache 8.2% (placebo 4.9%)
hypertension 4.9% (placebo 6.6%)
NCT01636687 · Phase 3
300 mg
dermatitis contact 5.9% (placebo 3.9%)
nasopharyngitis 5.9% (placebo 2%)
diarrhoea 3.9% (placebo 3.9%)
NCT02267135 · Phase 3
300 mg (2x1mL PFS)
nasopharyngitis 11.3% (placebo 11.3%)
headache 8.5% (placebo 4.2%)
back pain 4.2% (placebo 2.8%)
NCT02748863 · Phase 3
300 mg (2mL PFS)
nasopharyngitis 9.7% (placebo 11.3%)
headache 8.3% (placebo 4.2%)
pruritus 6.9% (placebo 4.2%)
NCT02748863 · Phase 3
300 mg
nasopharyngitis 14.6% (placebo 0%)
hypertension 9.8% (placebo 0%)
influenza like illness 7.3% (placebo 2.5%)
NCT03589885 · Phase 3
itch 20%
bruising 10%
felt cramped 10%
NCT04717466 · Phase 4 · registry result, not featured evidence
300 mg
headache 9.8%
nasopharyngitis 9.8%
upper respiratory tract infection 7.1%
NCT03020199 · Phase 4 · registry result, not featured evidence
300 mg
arthralgia 5.7%
nasopharyngitis 3.4%
headache 1.1%
NCT03020199 · Phase 4 · registry result, not featured evidence
300 mg
nasopharyngitis 18.5%
upper respiratory tract infection 13%
back pain 7.4%
NCT03055494 · Phase 4 · registry result, not featured evidence
upper respiratory infection 60%
cough 20%
diarrhea 13.3%
NCT02592018 · Phase 4 · registry result, not featured evidence
300 mg
nasopharyngitis 19.6%
upper respiratory tract infection 13%
arthralgia 10.9%
NCT02690701 · Phase 4 · registry result, not featured evidence
nasopharyngitis 20.6%
dermatitis contact 5.9%
hypertension 5.9%
NCT02547714 · Phase 4 · registry result, not featured evidence
nasopharyngitis 11.8%
alopecia 2.9%
dermatitis contact 2.9%
NCT02547714 · Phase 4 · registry result, not featured evidence
covid-19 21.4%
nasopharyngitis 16.7%
viral upper respiratory tract infection 16.7%
NCT03668613 · Phase 3 · registry result, not featured evidence
nasopharyngitis 31%
covid-19 26.2%
acne 16.7%
NCT03668613 · Phase 3 · registry result, not featured evidence
300 mg every 2 weeks
nasopharyngitis 19.4%
upper respiratory tract infection 7.3%
headache 6.7%
NCT03504852 · Phase 3 · registry result, not featured evidence
300 mg every 4 weeks
nasopharyngitis 16.4%
upper respiratory tract infection 6.7%
oropharyngeal pain 5.2%
NCT03504852 · Phase 3 · registry result, not featured evidence
300 mg every 4 weeks (up-titration)
nasopharyngitis 16.1%
intertrigo 9.7%
neutrophil count decreased 9.7%
NCT03504852 · Phase 3 · registry result, not featured evidence
300 mg
upper respiratory tract infection 24.6% (placebo 9.6%)
hyperuricaemia 20.6% (placebo 12.6%)
nasopharyngitis 16.2% (placebo 3.7%)
NCT03066609 · Phase 3 · registry result, not featured evidence
150 mg
upper respiratory tract infection 30.1% (placebo 9.6%)
hyperuricaemia 18.4% (placebo 12.6%)
influenza 12.5% (placebo 3%)
NCT03066609 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 10%
upper respiratory tract infection 8.9%
diarrhoea 4.7%
NCT02826603 · Phase 3 · registry result, not featured evidence
300 mg
hypertension 4.1%
pruritus 1.6%
NCT02394561 · Phase 3 · registry result, not featured evidence
300 mg
pruritus 6.5%
hypertension 5.9%
NCT02394561 · Phase 3 · registry result, not featured evidence
300 mg
viral upper respiratory tract infection 39.2% (placebo 15.4%)
pustular psoriasis 20.3% (placebo 5.1%)
headache 15.2% (placebo 12.8%)
NCT02008890 · Phase 3 · registry result, not featured evidence
150 mg
pustular psoriasis 23.8% (placebo 5.1%)
viral upper respiratory tract infection 21.3% (placebo 15.4%)
headache 8.8% (placebo 12.8%)
NCT02008890 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 14.6% (placebo 23.7%)
headache 4.8% (placebo 1.1%)
back pain 2.8% (placebo 1.1%)
NCT02409667 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 14.4% (placebo 23.7%)
back pain 4.2% (placebo 1.1%)
headache 4.1% (placebo 1.1%)
NCT02409667 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 20.2% (placebo 23.7%)
psoriasis 9.6% (placebo 8.6%)
upper respiratory tract infection 6.1% (placebo 5.4%)
NCT02409667 · Phase 3 · registry result, not featured evidence
300 mg
back pain 10.8%
nasopharyngitis 10.8%
diarrhoea 10%
NCT02595970 · Phase 3 · registry result, not featured evidence
300 mg s.c. (2-weekly)
nasopharyngitis 16.6%
headache 3.1%
hypertension 2.5%
NCT02474069 · Phase 3 · registry result, not featured evidence
300 mg s.c. (4-weekly)
nasopharyngitis 14.2%
headache 3.1%
arthralgia 2.5%
NCT02474069 · Phase 3 · registry result, not featured evidence
300 mg s.c. (4-weekly)
nasopharyngitis 21.8%
headache 7.8%
diarrhoea 4.4%
NCT02474069 · Phase 3 · registry result, not featured evidence
nasopharyngitis 28.6% (placebo 28.9%)
headache 7.1% (placebo 2.6%)
hypertension 4.8% (placebo 5.3%)
NCT02362789 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 29.1%
oropharyngeal pain 16.2%
headache 15.6%
NCT01961609 · Phase 3 · registry result, not featured evidence
150 mg
headache 23.5%
nasopharyngitis 23.5%
psoriasis 13%
NCT01961609 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 28.7%
headache 14.9%
upper respiratory tract infection 12.5%
NCT02074982 · Phase 3 · registry result, not featured evidence
nasopharyngitis 51.4%
headache 14.3%
diarrhoea 6.7%
NCT02474082 · Phase 3 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 52 weeks versus 24 weeks.
  5. eAssessment timepoints differ: 32 weeks versus 52 weeks.
  6. fTrial phases differ: Phase 4 versus Phase 3.
  7. gAssessment timepoints differ: 4 weeks versus 192 weeks.
  8. hTrial phases differ: Phase 3 versus Phase 2.
  9. iAssessment timepoints differ: 4 weeks versus 52 weeks.
  10. jPopulation context differs: registered conditions differ.
  11. kTrial phases differ: Phase 3 versus Phase 4.
  12. lAssessment timepoints differ: 32 weeks versus 24 weeks.
  13. mAssessment timepoints differ: 132 weeks versus 52 weeks.
  14. nPopulation comparability has not been reviewed for 76 of these studies.
  15. oPopulation comparability has not been reviewed for 78 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ixekizumab

sPGA (0 36% (n=386) vs 0% (n=193) placebo @ 12wk80 mg every 4 weeks
responder rate · % of participants
Induction
NCT01646177 · Phase 3 · converted to % from 139 Participants as posted
show 10 more results
40.3% (n=385) vs 0% (n=193) placebo @ 12wk*80 mg every 2 weeks
NCT01646177 · Phase 3 · converted to % from 155 Participants as posted
35.6% (n=174) vs 0% (n=88) placebo @ 12wk80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
36.4% (n=176) vs 0% (n=88) placebo @ 12wk80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
34.5% (n=432) vs 0% (n=431) placebo @ 12wkQ4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
37% (n=433) vs 0% (n=431) placebo @ 12wkQ2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
32.3% (n=347) vs 0.6% (n=168) placebo @ 12wkQ4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
41.9% (n=351) vs 0.6% (n=168) placebo @ 12wkQ2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
52.2% (n=115) vs 1.8% (n=56) placebo @ 12wk
NCT03073200 · Phase 3
41.9% (n=520) vs 25.2% (n=507) Guselkumab @ 12wk
NCT03573323 · Phase 4 · registry result, not featured evidence
41.9% (n=136) vs 18.1% (n=166) Ustekinumab @ 12wk
NCT02561806 · Phase 3 · registry result, not featured evidence
PASI 90 64.6% (n=432) vs 0.5% (n=431) placebo @ 12wkQ4W
responder rate · % of participants
Induction
PASI90
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 1 more result
70.9% (n=433) vs 0.5% (n=431) placebo @ 12wkQ2W
PASI90
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
PASI 100 33.6% (n=432) vs 0% (n=431) placebo @ 12wkQ4W
responder rate · % of participants
Induction
PASI100
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 1 more result
35.3% (n=433) vs 0% (n=431) placebo @ 12wkQ2W
PASI100
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
sPGA 0/1 37.4% (n=227) vs 7.5% (n=226) placebo @ 60wkQ12W
responder rate · % of participants
Maintenance
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 4 more results
72.9% (n=229) vs 7.5% (n=226) placebo @ 60wkQ4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
65.4% (n=52) vs 17.1% (n=41) placebo @ 24wkQ4W
NCT01695239 · Phase 3
73.2% (n=41) vs 17.1% (n=41) placebo @ 24wkQ2W
NCT01695239 · Phase 3
86.5% (n=52) vs 13.2% (n=53) Fumaric Acid Esters @ 24wk
NCT02634801 · Phase 3 · registry result, not featured evidence
Itch NRS 80.5% (n=379) vs 15.5% (n=374) placebo @ 12wkQ4W
responder rate · % of participants
Induction
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 1 more result
85.9% (n=391) vs 15.5% (n=374) placebo @ 12wkQ2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
NAPSI -9.9793 vs 1.6362 placebo score @ 12wk80 mg every 4 weeks
absolute change · score
Induction
NCT01646177 · Phase 3
show 13 more results
-10.4145 vs 1.6362 placebo score @ 12wk80 mg every 2 weeks
NCT01646177 · Phase 3
-11.35 vs -1.26 placebo score @ 12wk80 mg Q4W
NCT03364309 · Phase 3 · registry result, not featured evidence
-10.07 vs -1.26 placebo score @ 12wk80 mg Q2W
NCT03364309 · Phase 3 · registry result, not featured evidence
-19.91 vs 2.21 placebo score @ 12wk150 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-15.89 vs 2.21 placebo score @ 12wk75 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-3.65 vs 2.21 placebo score @ 12wk25 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-4.85 vs 2.21 placebo score @ 12wk10 mg
NCT01107457 · Phase 2 · registry result, not featured evidence
-7.19 vs 2.17 placebo score @ 12wkQ4W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
-7.24 vs 2.17 placebo score @ 12wkQ2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
-7.39 vs -0.82 placebo score @ 12wkQ4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
-8.6 vs -0.82 placebo score @ 12wkQ2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
-16.87 vs 0.17 placebo score @ 12wk
NCT03073200 · Phase 3
-12.24 vs -5.02 Ustekinumab score @ 12wk
NCT02561806 · Phase 3 · registry result, not featured evidence
PatGA -3.1 vs -0.2 placebo score @ 12wkQ4W
absolute change · score
Induction
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
show 4 more results
-3.2 vs -0.2 placebo score @ 12wkQ2W
NCT01474512 · Phase 3 · combination · Psoriasis · phase 3
-3 vs -0.4 placebo score @ 12wkQ4W
NCT01597245 · Phase 3 · Psoriasis · phase 3
-3.2 vs -0.4 placebo score @ 12wkQ2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
-3.07 vs -2.6 Ustekinumab score @ 12wk
NCT02561806 · Phase 3 · registry result, not featured evidence
Itch NRS ≥4 Point Reduction 76.8% (n=293) vs 14.1% (n=135) placebo @ 12wkQ4W
responder rate · % of participants
Induction
NCT01597245 · Phase 3 · Psoriasis · phase 3
show 1 more result
85.1% (n=303) vs 14.1% (n=135) placebo @ 12wkQ2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
BSA -20.3 vs 0.5 placebo score @ 12wkQ4W
absolute change · score
Induction
NCT01597245 · Phase 3 · Psoriasis · phase 3
show 1 more result
-20.6 vs 0.5 placebo score @ 12wkQ2W
NCT01597245 · Phase 3 · Psoriasis · phase 3
PPASI 50 85.3% (n=102) vs 43.6% (n=55) placebo @ 12wkQ4W
responder rate · % of participants
Induction
PPASI 50
NCT01597245 · Phase 3 · Psoriasis · phase 3
show 1 more result
88.5% (n=104) vs 43.6% (n=55) placebo @ 12wkQ2W
PPASI 50
NCT01597245 · Phase 3 · Psoriasis · phase 3
PPASI 75 80.4% (n=102) vs 30.9% (n=55) placebo @ 12wkQ4W
responder rate · % of participants
Induction
PPASI 75
NCT01597245 · Phase 3 · Psoriasis · phase 3
show 1 more result
79.8% (n=104) vs 30.9% (n=55) placebo @ 12wkQ2W
PPASI 75
NCT01597245 · Phase 3 · Psoriasis · phase 3
PPASI 100 69.6% (n=102) vs 25.5% (n=55) placebo @ 12wkQ4W
responder rate · % of participants
Induction
PPASI 100
NCT01597245 · Phase 3 · Psoriasis · phase 3
show 1 more result
71.2% (n=104) vs 25.5% (n=55) placebo @ 12wkQ2W
PPASI 100
NCT01597245 · Phase 3 · Psoriasis · phase 3

+ 101 further endpoints in the CSV export.

secukinumab

PASI 75 Response Maintenance 84.3% (n=249) vs 72.5% (n=142) Etanercept @ 52wk300mg
event count · % of participants
Maintenance
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 210 participants who reached goal as posted
show 1 more result
82.2% (n=219) vs 72.5% (n=142) Etanercept @ 52wk*150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 180 participants who reached goal as posted
sPGA 0 1 Response Maintenance 79.7% (n=202) vs 56.8% (n=88) Etanercept @ 52wk300mg
event count · % of participants
Maintenance
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 161 participants who reached goal as posted
show 1 more result
67.7% (n=167) vs 56.8% (n=88) Etanercept @ 52wk*150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 113 participants who reached goal as posted
Scaling -4.93 vs -0.42 placebo score @ 12wk300mg
absolute change · score
Induction
Scaling
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
show 3 more results
-4.93 vs -3.74 Etanercept score @ 12wk300mg
Scaling
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
-4.89 vs -0.42 placebo score @ 12wk150mg
Scaling
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
-4.89 vs -3.74 Etanercept score @ 12wk150mg
Scaling
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
IGA 0/1 65.3% (n=245) vs 2.4% (n=246) placebo @ 12wk300 mg
responder rate · % of participants
Induction
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
show 22 more results
69% (n=58) vs 0% (n=59) placebo @ 12wk300 mg
NCT01555125 · Phase 3
75.6% (n=41) vs 7.5% (n=40) placebo @ 12wk*300 mg
NCT03589885 · Phase 3 · converted to % from 31 Participants as posted
78.7% (n=272) vs 3% (n=135) placebo @ 12wk*300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence · converted to % from 214 Participants as posted
72.2% (n=550) vs 55.4% (n=552) Ustekinumab @ 12wk*300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence · converted to % from 397 Participants as posted
78.5% (n=550) vs 59.1% (n=552) Ustekinumab @ 16wk*300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence · converted to % from 432 Participants as posted
51.2% (n=244) vs 2.4% (n=246) placebo @ 12wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
52.5% (n=59) vs 0% (n=59) placebo @ 12wk150 mg
NCT01555125 · Phase 3
67.6% (n=136) vs 3% (n=135) placebo @ 12wk*150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence · converted to % from 92 Participants as posted
56.9% (n=51) vs 5.9% (n=51) placebo @ 12wk
NCT02267135 · Phase 3
52.9% (n=51) vs 3.9% (n=51) placebo @ 12wk
NCT02267135 · Phase 3
76.4% (n=72) vs 1.4% (n=71) placebo @ 12wk*2 mL PFS
NCT02748863 · Phase 3 · converted to % from 55 participants as posted
70% (n=40) vs 5% (n=40) placebo @ 12wk*low dose
NCT02471144 · Phase 3 · converted to % from 28 Participants as posted
60% (n=40) vs 5% (n=40) placebo @ 12wk*high dose
NCT02471144 · Phase 3 · converted to % from 24 Participants as posted
78.3% (n=46) vs 0% (n=45) placebo @ 12wk
NCT02690701 · Phase 4 · registry result, not featured evidence
0% (n=105) vs 0% (n=95) Fumaric Acid @ 1wk
NCT02474082 · Phase 3 · registry result, not featured evidence
5.7% (n=105) vs 0% (n=95) Fumaric Acid @ 2wk
NCT02474082 · Phase 3 · registry result, not featured evidence
13.3% (n=105) vs 1.1% (n=95) Fumaric Acid @ 3wk
NCT02474082 · Phase 3 · registry result, not featured evidence
34.3% (n=105) vs 1.1% (n=95) Fumaric Acid @ 4wk
NCT02474082 · Phase 3 · registry result, not featured evidence
50.5% (n=105) vs 2.1% (n=95) Fumaric Acid @ 6wk
NCT02474082 · Phase 3 · registry result, not featured evidence
66.7% (n=105) vs 4.2% (n=95) Fumaric Acid @ 8wk
NCT02474082 · Phase 3 · registry result, not featured evidence
77.1% (n=105) vs 12.6% (n=95) Fumaric Acid @ 12wk
NCT02474082 · Phase 3 · registry result, not featured evidence
80% (n=105) vs 14.7% (n=95) Fumaric Acid @ 16wk
NCT02474082 · Phase 3 · registry result, not featured evidence
PASI -89.55% (n=245) vs -63.1% (n=18) placebo @ 13wk300 mg
percent change · % of baseline
Maintenance
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
show 51 more results
-21.66% (n=105) vs -63.1% (n=18) placebo @ 13wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-90.83% (n=245) vs -68.74% (n=18) placebo @ 14wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-41.97% (n=105) vs -68.74% (n=18) placebo @ 14wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-91.4% (n=245) vs -67.15% (n=18) placebo @ 15wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-57.77% (n=105) vs -67.15% (n=18) placebo @ 15wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-91.37% (n=245) vs -73.38% (n=18) placebo @ 16wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-70.15% (n=105) vs -73.38% (n=18) placebo @ 16wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-90.86% (n=245) vs -80.57% (n=18) placebo @ 20wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-84.53% (n=105) vs -80.57% (n=18) placebo @ 20wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-90.83% (n=245) vs -78.06% (n=18) placebo @ 24wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.2% (n=105) vs -78.06% (n=18) placebo @ 24wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-90.15% (n=245) vs -79.55% (n=18) placebo @ 28wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-91.24% (n=105) vs -79.55% (n=18) placebo @ 28wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.9% (n=245) vs -75.94% (n=18) placebo @ 32wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-91.09% (n=105) vs -75.94% (n=18) placebo @ 32wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-90.04% (n=245) vs -78.37% (n=18) placebo @ 36wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.97% (n=105) vs -78.37% (n=18) placebo @ 36wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.62% (n=245) vs -78.32% (n=18) placebo @ 40wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.76% (n=105) vs -78.32% (n=18) placebo @ 40wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-88.97% (n=245) vs -79.96% (n=18) placebo @ 44wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.37% (n=105) vs -79.96% (n=18) placebo @ 44wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.35% (n=245) vs -79.54% (n=18) placebo @ 48wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-88.44% (n=105) vs -79.54% (n=18) placebo @ 48wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-88.42% (n=245) vs -79.64% (n=18) placebo @ 52wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-87.66% (n=105) vs -79.64% (n=18) placebo @ 52wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.12% (n=245) vs -63.1% (n=18) placebo @ 13wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-21.03% (n=108) vs -63.1% (n=18) placebo @ 13wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-84.47% (n=245) vs -68.74% (n=18) placebo @ 14wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-39.2% (n=108) vs -68.74% (n=18) placebo @ 14wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-84.67% (n=245) vs -67.15% (n=18) placebo @ 15wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-51.78% (n=108) vs -67.15% (n=18) placebo @ 15wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-85.2% (n=245) vs -73.38% (n=18) placebo @ 16wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-62.19% (n=108) vs -73.38% (n=18) placebo @ 16wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-85.75% (n=245) vs -80.57% (n=18) placebo @ 20wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-77.75% (n=108) vs -80.57% (n=18) placebo @ 20wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-85.46% (n=245) vs -78.06% (n=18) placebo @ 24wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.19% (n=108) vs -78.06% (n=18) placebo @ 24wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-84.72% (n=245) vs -79.55% (n=18) placebo @ 28wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-84.07% (n=108) vs -79.55% (n=18) placebo @ 28wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.98% (n=245) vs -75.94% (n=18) placebo @ 32wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-84.26% (n=108) vs -75.94% (n=18) placebo @ 32wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-81.87% (n=245) vs -78.37% (n=18) placebo @ 36wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.68% (n=108) vs -78.37% (n=18) placebo @ 36wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-81.37% (n=245) vs -78.32% (n=18) placebo @ 40wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-82.83% (n=108) vs -78.32% (n=18) placebo @ 40wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-80.81% (n=245) vs -79.96% (n=18) placebo @ 44wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.44% (n=108) vs -79.96% (n=18) placebo @ 44wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-79.78% (n=245) vs -79.54% (n=18) placebo @ 48wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.4% (n=108) vs -79.54% (n=18) placebo @ 48wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-79.74% (n=245) vs -79.64% (n=18) placebo @ 52wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-82.14% (n=108) vs -79.64% (n=18) placebo @ 52wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
Time to Response 1.87 vs NA placebo months @ 12wk300 mg
time to event · months
Induction
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to months from 57 days as posted
show 1 more result
1.87 vs NA placebo months @ 12wk*150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to months from 57 days as posted
DLQI -62.5% (n=245) vs -5% (n=247) placebo @ 4wk300 mg
percent change · % of baseline
Induction
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
show 9 more results
-81.5% (n=245) vs -8.3% (n=247) placebo @ 8wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-86.4% (n=245) vs -9.1% (n=247) placebo @ 12wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-85% (n=53) vs -16.7% (n=54) placebo @ 12wk300 mg
NCT01555125 · Phase 3
-86.8% (n=55) vs -17.9% (n=55) placebo @ 12wk300 mg
NCT01636687 · Phase 3
-55% (n=245) vs -5% (n=247) placebo @ 4wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-73.1% (n=245) vs -8.3% (n=247) placebo @ 8wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-77.8% (n=245) vs -9.1% (n=247) placebo @ 12wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-78.6% (n=56) vs -16.7% (n=54) placebo @ 12wk150 mg
NCT01555125 · Phase 3
-83.3% (n=56) vs -17.9% (n=55) placebo @ 12wk150 mg
NCT01636687 · Phase 3
DLQI -86.4% (n=245) vs -58.3% (n=18) placebo @ 12wk300 mg
percent change · % of baseline
Maintenance
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
show 17 more results
-4.4% (n=105) vs -58.3% (n=18) placebo @ 12wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.6% (n=245) vs -76.6% (n=18) placebo @ 24wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.3% (n=105) vs -76.6% (n=18) placebo @ 24wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-91.7% (n=245) vs -77.9% (n=18) placebo @ 36wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-90% (n=105) vs -77.9% (n=18) placebo @ 36wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-88.9% (n=245) vs -64.4% (n=18) placebo @ 52wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-88.9% (n=105) vs -64.4% (n=18) placebo @ 52wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-91.2% (n=55) vs -53.7% (n=3) placebo @ 52wk300 mg
NCT01636687 · Phase 3
-77.8% (n=245) vs -58.3% (n=18) placebo @ 12wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-7.1% (n=108) vs -58.3% (n=18) placebo @ 12wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.3% (n=245) vs -76.6% (n=18) placebo @ 24wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.3% (n=108) vs -76.6% (n=18) placebo @ 24wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-78.6% (n=245) vs -77.9% (n=18) placebo @ 36wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-78.5% (n=108) vs -77.9% (n=18) placebo @ 36wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-76.5% (n=245) vs -64.4% (n=18) placebo @ 52wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-75% (n=108) vs -64.4% (n=18) placebo @ 52wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-90.9% (n=56) vs -53.7% (n=3) placebo @ 52wk150 mg
NCT01636687 · Phase 3
IGA 0/1 71.2% (n=59) @ 52wk300 mg
responder rate · % of participants
No placebo or comparator arm
NCT01555125 · Phase 3
show 17 more results
73.9% (n=165) @ 16wk*300 mg every 2 weeks
NCT03504852 · Phase 3 · registry result, not featured evidence · converted to % from 122 Participants as posted
65.7% (n=166) @ 16wk*300 mg every 4 weeks
NCT03504852 · Phase 3 · registry result, not featured evidence · converted to % from 109 Participants as posted
19.4% (n=772) @ 4wk*300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 150 Participants as posted
57.8% (n=772) @ 16wk*300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 446 Participants as posted
41.4% (n=162) @ 18wk*300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 67 Participants as posted
41.7% (n=163) @ 18wk*300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 68 Participants as posted
54.3% (n=162) @ 22wk*300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 88 Participants as posted
55.2% (n=163) @ 22wk*300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 90 Participants as posted
53.7% (n=162) @ 26wk*300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 87 Participants as posted
68.1% (n=163) @ 26wk*300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 111 Participants as posted
59.9% (n=162) @ 30wk*300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 97 Participants as posted
65% (n=163) @ 30wk*300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 106 Participants as posted
60.5% (n=162) @ 32wk*300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 98 Participants as posted
68.1% (n=163) @ 32wk*300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 111 Participants as posted
51% (n=59) @ 52wk150 mg
NCT01555125 · Phase 3
78.6% (n=42) @ 12wk*
NCT03668613 · Phase 3 · registry result, not featured evidence · converted to % from 33 Participants as posted
83.3% (n=42) @ 12wk*
NCT03668613 · Phase 3 · registry result, not featured evidence · converted to % from 35 Participants as posted
EQ-5D 11.2 vs 0.8 placebo score @ 12wk300 mg
absolute change · score
Induction
NCT01555125 · Phase 3
show 3 more results
15.3 vs -0.5 placebo score @ 12wk300 mg
NCT01636687 · Phase 3
12.1 vs 0.8 placebo score @ 12wk150 mg
NCT01555125 · Phase 3
13.5 vs -0.5 placebo score @ 12wk150 mg
NCT01636687 · Phase 3
EQ-5D 13.5 score @ 52wk300 mg
absolute change · score
Maintenance
No placebo or comparator arm
NCT01555125 · Phase 3
show 1 more result
11.4 score @ 52wk150 mg
NCT01555125 · Phase 3
DLQI -90.5% (n=56) @ 52wk300 mg
percent change · % of baseline
Maintenance
No placebo or comparator arm
NCT01555125 · Phase 3
show 1 more result
-71.4% (n=57) @ 52wk150 mg
NCT01555125 · Phase 3

+ 135 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ixekizumab's landscape · secukinumab's landscape